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1 
TARGETED DRUG DELIVERY SYSTEM 
Targeted drug delivery is a kind of smart drug delivery system which is miraculous in 
delivering the drug to a patient. This conventional drug delivery system is done by the 
absorption of the drug across a biological membrane, whereas the targeted release system is 
that drug is released in a dosage form [1, 2]. 
Targeted drug delivery system is based on a method that delivers a certain amount of 
a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. 
This helps maintain the required plasma and tissue drug levels in the body; therefore avoiding 
any damage to the healthy tissue via the drug. The drug delivery system is highly integrated 
and requires various disciplines, such as chemists, biologist and engineers, to join forces to 
optimize this system. When implementing a targeted release system, the following design 
criteria for the system need to take into account: the drug properties, side effects of the drugs, 
the route taken for the delivery of the drug, the targeted site, and the disease [1, 3, 4]. 
Products based on such a delivery system are being prepared by considering the 
specific properties of target cells, nature of markers or transport carriers or vehicles which 
convey drug to specific receptors and ligands and physically modulated components. Ideally 
targeted drug delivery systems should be biochemically inert (non-toxic), should be non-
immunogenic, should be physically and chemically stable in vivo and in vitro conditions, and 
should have restricted drug distribution to target cells or tissues or organs and should have 
uniform capillary distribution. It should have controllable and predictable rate of drug release 
and also drug release should not affect the drug action. It should have therapeutic amount of 
drug release and should have minimal drug leakage during transit [5, 4, 6]. 
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Carriers used should be bio-degradable or readily eliminated from the body without 
any problem. The preparation of the delivery system should be easy or reasonably simple, 
reproductive and cost effective.A Targeted drug delivery system is preferred over 
conventional drug delivery systems due to three main reasons. The first being pharmaceutical 
reason. Conventional drugs have low solubility and more drug instability in comparison to 
targeted drug delivery systems. Conventional drugs also have poor absorption, shorter half-
life and require large volume of distribution. These constitute its pharmacokinetic properties. 
The third reason constitutes the pharmacodynamic properties of drugs. The conventional 
drugs have low specificity and low therapeutic index as compared to targeted drug delivery 
system. Due to these reasons targeted drug delivery system is preferred over conventional 
drug delivery systems[1, 3, 4]. 
TYPES OF TARGETED DRUG DELIVERY 
As discussed, targeting drug to a specific area is not only increases the therapeutic 
efficacy of drugs also it aims to decreases the toxicity associated with drug to allow lower 
doses of the drug to be used in therapy. For the fulfilment of such conditions, two approaches 
are used extensively which also has known as classification of drug is targeting [7, 8, 1]. 
Passive targeting 
It refers to the accumulation of drug or drug carrier system at a specific site such as 
anti-cancerous drug whose explanation may be attributed to physicochemical or 
pharmacological factors of the disease. Hence, in case of cancer treatment the size and 
surface properties of drug delivery nano-particles must be controlled specifically to avoid 
uptake by theoretical-endothelial system (RES) to maximize circulation times and targeting 
ability. The bottom line is called passive targeting as misnomer which is simple drug delivery 
system via blood circulation. Drug releaseor drug actions are limited to selective sites within 
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the body such as a tumour but not the liver. Other examples include targeting of ant malarial 
drugs for treatment ofleishmiansis, brucellosis, candiadsis[7]. 
Active targeting 
Active targeting means a specific ligand–receptor type interaction for intracellular 
localization which occurs only after blood circulation and extravasations. This active 
targeting approach can be further classified into three different levels of targeting which are:  
1) First order targeting refers to restricted distribution of the drug carrier systems to the 
capillary bed of a predetermined target site, organ or tissue e.g. compartmental targeting 
in lymphatics, peritoneal cavity, plural cavity, cerebral ventricles and eyes, joints. 
2) Second order targeting refers to selective delivery of drugs to specific cell types such as 
tumour cells and notto the normal cells e.g. selective drug delivery tokupffer cells in the 
liver.  
3) Third order targeting refers to drug delivery specifically to the intracellular site of 
targeted cells e.g. receptor based ligand mediated entry of a drug complex into a cell by 
endocytosis [8]. 
COMPONENTS OF TARGETED DRUG DELIVERY 
A drug delivery system primarily constitutes a target and drug carriers or markers. 
Target means specific organ or a cell or group of cells, which in chronic or acute condition 
need treatment. Route of administration involves drug carrier as a important targeting moiety 
and after its leakage from its carrier/markers to reach the drug to the specific or targeted site 
via biological metabolism with its clearance as well as not to reach at non targeted site to 
make this delivery system more site specific with reduced side effects of drugs and its 
quantity too. Carriers one of the special molecule or system essentially required for effective 
transportation of loaded drug up to the pre-selected sites. These are engineered vectors which 
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retain drug inside or onto them either via encapsulation and/ or via spacer moiety and 
transport or deliver it into vicinity of target cell [7, 8, 9]. 
DRUG DELIVERY VEHICLES 
Drug delivery vehicles are also referred as drug vectors which are most important 
entity required for successful transportation of the loaded drug. Drug vectors transports and 
retains the drug to e delivered it within or in the vicinity of target. They are made capable of 
performing such specific functions which can be attributed by slight structural modification 
[10, 8, 1]
. 
CHARACTERISTICS OF AN IDEAL VEHICLE 
An ideal vehicle should be able to cross blood brain barriers and in case of 
tumourchemotherapy tumour vasculature. It must be recognized by the target cells 
specifically and selectively and must maintain the specificity of the surface ligands. The drug 
ligand complex should best able in plasma, interstitial and other bio-fluids. The vehicle used 
should be non-toxic, non-immunogenic and biodegradable.  
After recognition, the carrier system should release the drug moiety inside the target 
organs, tissues or cells. Targeting Moieties includes antibodies, lectins and other proteins, 
Lipoproteins, Hormones, Charged molecules, Polysaccharides and Low molecular- weight 
ligands [10,12, 11, 1]. 
Liposomes 
Liposomes are small artificially designed vesicles composed of phospholipids bilayers 
surrounding with the size ranging from 20 to 10 000 nm. Many liposome formulations are 
rapidly taken up by macrophages and this can be exploited either for macrophage-specific 
delivery of drugs or for passive drug targeting which allow slow release of the drug over time 
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from these cells into the general circulation. Cationic liposomes and lipoplexes have been 
extensively researched for their application in non-viral vector mediated gene therapy [13]. 
Monoclonal antibodies and fragments 
The majority of strategies based on antigen recognition by antibodies have been 
developed for more specifically for cancer therapy. These strategies are mostly aimed at 
tumor associated antigens being presenter in more specific term expressed by tumor cells. 
Antibody-drug conjugates (ADC) are complex of a drug with a monoclonal antibody which 
provides selective targeting for tumoral cell masses or lymphomas. The drug is released by 
enzymatic cleavage of the linker under physiological conditions. An example of Antibody-
drug conjugates (ADC) is Mylotarg (emtuzamabozogamicin) which was approved by the 
U.S. Food and Drug Administration (FDA), but later voluntarily withdrawn from the US 
market. Another ADC has been submitted for approval and at least 15antibody conjugates are 
currently being investigated in clinical trials [14]. 
Modified (plasma) proteins 
Modified plasma proteins can be intelligent drug vehicle for drug transportation due 
to their solubility and having relatively small molecular weight. They can easily be modified 
by the attachment of different molecules like peptides, sugars, and other ligands to transport 
the drugs of interest makes them a suitable mode of drug delivery. In the case of liver cell 
targeting, extensive modifications of protein backbones such as albumins have been carried 
out effective delivery of the drug [15]. 
Soluble synthetic polymers have been extensively researched as versatile drug carrier 
systems. Polymer chemistry allows the development of tailor made conjugates in which 
target moieties as well as drugs can be entrapped into the carrier molecule. Forcancertherapy, 
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the well-established N (-2-hydroxypropyl) methacrylamide (HMPA) polymershave been 
extensively studied. Also it provides a solution for selective and targeted chemotherapy. 
Microspheres and nanoparticles 
Microspheres and nanoparticles consist of biocompatible polymers and belong either 
to the soluble or the particle type carriers. HPMA polymeric backbone carriers have also been 
prepared using dextrans, ficoll, sepharose or poly-L-lysine as the main carrier body for the 
drugs. Nanoparticles are smaller (0.2– 0.5 μm) than microspheres (30–200 μm) and may have 
a smaller drug loading capacity than the soluble polymers. Formulation of drugs into the 
nanoparticles can occur at the surface of the particles and in nucleus, depending on the 
physicochemical characteristics of the drug. The site of drug incorporation significantly 
affects its release rate from the particle. After systemic administration ortransportation, they 
quickly distribute to the target sit and subsequently become internalized by the cells ofthe 
phagocytic system. Besides, microspheres and nanoparticles which are mostly used for cell 
selective delivery of drugs, they have more recently been studied for their application in oral 
delivery of peptides and peptidomimetics[16,17,12,18]. 
Lipoproteins 
Lipid particles such as LDL and HDL containing a lipid and an apo-protein moiety is 
termed as natural targeted liposomes and its core can be used to incorporate lipophilic drugs 
or lipophilic pro-drugs and it does not require covalent bonding with the drug. Modifications 
at the level of glycolipid incorporation can be used to introduce new targeting moieties. The 
majority of the research on the use of LDL and HDL particles has been done and improved at 
the level of targeting the drugs to the liver [19]. 
Quantum dots 
A quantum dot is a semiconductor nanostructure that confines the motion of 
conduction band electrons, valence band holes or bound pairs of conduction band electrons 
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and valence band holes in all three spatial directions. The ability to tune the size of quantum 
dots is advantageous for many applications and it is one of the most promising candidates as 
vehicle for drug transportation with its in solid-state quantum computation used for diagnosis, 
drug delivery, Tissue engineering, catalysis, filtration and textiles technologies too . 
Folate Targeting 
Folate targeting is a method utilized in biotechnology for drug delivery purposes. It 
involves the attachment of the vitamin, folate (folic acid) to drug to form folate conjugate. 
Based on the natural high affinity of folate for the folate receptor protein (FR)which is 
commonly expressed on the surface of cancer cells and folate-drug conjugates also bind 
tightly to the foliate receptor protein(FR)which in turn, triggerellular uptake via endocytosis. 
The folate receptor protein (FR) is also a recognized tumor antigen/biomarker. Because of 
this inherent property off late receptor protein (FR), exploits its use in diagnostic and 
therapeutic methods especially for the treatment of cancer [20]. 
Delivery of drug molecule to reach its specific site is itself a difficult task in the 
complex cellular network of an organism. Finally, targeted drug delivery is coming forward 
as one of the brightest advanced techniques in the medical sciences in the diagnosis and 
treatment of couple of lethal diseases. It has crossed the infancy period and now touching 
height of growths in research and development in clinical and pharmaceutical fields. Overall, 
it may be concluded with the vast database of different studies, the science of site specific or 
targeted delivery of these drugs has become wiser and intelligent with time and the 
advancement of scientific technology. Manifestation of all these strategies and advanced 
technologies in clinical field leads to new era of therapeutic and diagnostics in future. Many 
problems which appeared during the development of drug targeting strategies for clinical 
application for different types of therapies have been identified, analyzed and solved 
especially in the treatment of cancer. Several such preparations have entered the phases of 
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clinical testing or trials have now been marketed. However, such strategies should be 
subjected to continuous evaluation in the light of advances in the understanding of the 
numerous processes occurring in response to administration of the carriers or vehicles with 
drugs of interest with site specificity [21]. 
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BIODEGRADABLE POLYMERS 
Biodegradable polymers are generally divided into two groups, natural and synthetic 
based on their origin. Synthetic origin polymers offer advantages over natural polymers by 
being versatile with a wide spectrum of applications, having a capability to tailor mechanical 
properties and altering the rate of degradation according to the need. On the other hand, 
natural polymers seem to be attractive due to their excellent biocompatibility, but they have 
not been fully investigated due to their undesirable properties like antigen city and batch-to-
batch variation. [22-24] 
The instability of the polymers leading to biodegradation has proven to be immensely 
important in many medical applications.[25] Biodegradable polymers offer tremendous 
potential in many exciting applications like drug delivery, tissue engineering, gene therapy, 
regenerative medicine, temporary implantable devices, coatings on implants, etc.[26–29] The 
basic criteria for selecting a polymer for use as a degradable biomaterial are to match the 
mechanical properties and the degradation rate to the needs of the application, non-toxic 
degradation products, biocompatibility, shelf life/stability, process ability and cost. [22,29] The 
mechanical properties should match the application so that sufficient strength remains until 
the surrounding tissue has been healed.[30]There are many polymers available for different 
application where the choice of the polymer is dependent on the requirements that a particular 
biomaterial demands. With respect to drug delivery, it is the time of release that governs the 
type of polymer, size and shape of the device.[22, 31] However, clinically approved polymers 
such as lactide and glycolide polymers are the polymer of choice for any application. 
Polymers found a multitude of uses in the medical industry, beginning with 
biodegradable sutures first approved in the 1960s. [31] Polyesters which are the representative 
class of biodegradable synthetic polymers continue to remain attractive in many clinical 
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applications due to their unique properties. Other classes of polymers which made a 
significant contribution to the field of biomaterials include polyurethanes, polyanhydrides, 
polyaminoacids, etc.[23,25, 32,33] Some of the natural polymers which are found to be 
biocompatible are extensively investigated which lead to some breakthrough innovations like 
Abraxane (paclitaxel-loaded albumin particles) based on nab technology.[34] 
 
Fig NO: 1 – VARIOUS TYPES OF BIODEGRADABLE POLYMERS 
There are various successful products in clinical practice, and the number of such 
products is ever increasing and at a faster rate from the past few decades.[22,35] Attempts have 
been made to develop injectable polymer compositions for use in tissue engineering 
applications which offer many advantages like avoiding surgery, filling cavities with complex 
geometries, and providing good bonding to tissue.[30] The inability of a single biodegradable 
polymer to meet all the requirements for biomedical scaffolds leads to the development of 
biodegradable polymer matrix nano composites in the field of tissue engineering. These nano 
composites increase and modulate mechanical, electrical and degradation properties. Polymer 
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matrix composites have the advantage of being very versatile, allowing fine tuning of their 
final properties. Biodegradable copolymers exhibiting temperature-responsive sol–gel 
transition have recently drawn much attention with their promising application in the fields of 
drug delivery, cell implantation and tissue engineering.[36] This class of copolymers exhibit 
amphiphilic nature due to the presence of hydrophilic (PEG)/hydrophobic segments 
(PLA/PLGA/PCL). These injectable hydrogels can be implanted in the human body with 
minimal surgical invasion. Strategies based on gene delivery or gene-activating biomaterials 
have a great potential in regenerative medicine, but the long-term safety of such therapies 
remains to be proven.[37] 
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SODIUM ALGINATE – A WONDER POLYMER FOR 
CONTROLLED DRUG DELIVERY 
The design and interest in controlled release dosage forms, has been increasing 
steadily during the last 50 years. In most works the purpose is to make a formulation that 
keeps a prolonged therapeutic effect at a reduced dosing frequency. It is worthless to mention 
that the drugs are almost never administered in an unformulated state. Generally a dosage 
form consists of one or more active principles together with a varying number of other 
substances (excipients). These excipients enormously influence the physicochemical 
characteristics of the final products. It is now recognized that excipients can potentially 
influence the rate and/or extent of absorption of a drug (e.g. by complex formation). 
Therefore a well-established formulation depends on the careful selection of excipients. By 
reviewing the present and past scenario it is never worthless to mention, the use of polymers 
as a formulation aid in controlled drug delivery systems become an important area of research 
and development [38]. 
 The current trend points to an increasing interest in the use of natural substances in 
food, drugs and cosmetics. The naturally occurring alginate polymers have a great potential 
in drug formulation due to their extensive application as food additives and their recognized 
lack of toxicity. Alginate is a nostalgic term for dietetic, biotechnology, cosmetic and 
pharmaceutical industries. As this group of polymers possesses a number of characteristics 
that makes it useful as a formulation aid, both as a conventional excipients and more 
specifically as a tool in polymeric-controlled drug delivery [38]. 
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The alginates were discovered by a British Pharmacist, E.C.C. Stanford; commercial 
production started in 1929. The annual production of alginates in the world is about 30,000 
tones; 30% of this is utilized by the food industry, the rest being used in industrial, 
pharmaceutical and dental applications [39, 40]. 
SOURCES OF ALGINATES: 
Alginic acid and its salts [Ca, Mg, Na& K] are abundantly present in brown algae 
(pheophyta) of the genera “Macrocystis, Laminaria, Ascophyllum, Alario, Ecklonia, Eisenia, 
Nercocystis, Sargassum, Cystoseira, and Fucus. The most important are species of Laminaria 
known as kelps or sea tangles and specimens of Fucus known as Wracks [41]. However, it is 
two species, Macrocystis porifera and Ascophyllum nodosum, that provide the bulk of 
alginates production in the world [42]. In the algal thalus, Phycocolloids are the primary 
components of both the cell wall and the extra cellular matrix; their function as a “skeleton” 
increasing the mechanical strength and the flexibility of the tissue probably due to their 
ability to accumulate divalent metal ions and form gels of the required mechanical strength 
with these ions. Acetylated alginates are also isolated from some bacteria genera 
pseudomonas and Acetobacter[43, 44, 46,46]. Red algae belonging to the family coralenacease 
also contain these substances [47,48]. 
EXTRACTION AND PREPARATION: 
Since alginates occur in the form of insoluble calcium, magnesium, sodium and 
potassium salts contained in the algal cell walls and the extra cellular matrix, their extraction 
and purification generally involve ion exchange techniques; the details of the extraction 
methods are usually protected by patents. Generally to prepare alginates for commercial use, 
the algae is mechanically harvested and dried before further processing except for M. Pyrifera 
which is processed in wet. Alginates are then extracted from dried and milled algal material 
after treatment with dilute mineral acid to remove or degrade associated neutral 
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homopolysaccharides such as laminarin and fucoidin. Concurrently the alkaline earth 
captions are exchanged for H+. The alginate is then converted from the insoluble protonated 
form to the soluble sodium salt by addition of sodium carbonate at a pH below 10. After 
extraction, the alginate can be further purified and then converted to either a salt or acid [49]. 
The alginates being obtained from a natural source are likely to have a variety of impurities 
potentially be present. These include heavy metals, endotoxin, proteins, other carbohydrates 
and polyphenols. For applications in the food and beverage industry, low levels of these 
impurities do not pose a problem, but for pharmaceutical applications; particularly when 
alginates will be administered via parenteral route, these impurities should be removed [50].  
CHEMICAL STRUCTURE OF ALGINATES:  
Chemically alginates are linear, unbranched polysaccharide composed of monomers 
of b-D Mannuronic acid (M) and it‟s C-5 epimer a –l guluronic acid(G) residues joined 
together by (1-4) glycoside linkages (Fig.2) The residues generally vary widely in 
composition and sequence and are arranged in a pattern of blocks along the chain. These 
homopolymeric regions of b-D mannuronic acid blocks and a-L guluronic acid blocks are 
inter-dispersed with regions of alternating structure (b-D-mannuronic acid –a-l-guluronic acid 
blocks). The composition and extent of the sequences and the molecular weight determine the 
physical properties of the alginates. The molecular variability is dependent on the organism 
and tissue from which the alginates are isolated. For example, alginates prepared from the 
stipes of old L. hyperborea kelp contain the highest content of a-Lguluronic acid residues 
while alginates from A. Nodosum and L. Japonica have low content of a-L-guluronic acid 
blocks. As polymunnronic acid was found to dominate tissues of young algae; in older plants 
it is transformed into polyguluronic acid by the enzyme C5 -epimerase [51]. In mature tissues 
polymannuronic acid is located mainly in the extra- cellular spaces while polyguluronic acid 
occurs in the cell walls. [52] 
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FIG NO: 2 – CHEMICAL STRUCTURES OF COMPONENTS OF THE ALGINIC ACID 
PROPERTIES OF ALGINATES: 
Solubility: Sodium alginates us slowly soluble in cold water, forming viscous, colloidal 
solution. It is insoluble in alcohol and hydro alcoholic solutions in which alcohol content is 
greater than 30% by weight. It is also insoluble in other organic solvents viz. Chloroform and 
ether, and in acids where the pH of the resulting solution falls below 3.0. A 1% solution in 
distilled water has a PH of approximately 7.2. Calcium alginate, is however, practically 
insoluble in water and organic solvents but soluble in sodium citrate [53]. 
 
Viscosity: Various grades of sodium alginates are available, yielding aqueous solutions of 
varying viscosity within a range of 20-400 centipoises (0.02-0.4 PaS) in 1% solution at 200C. 
Due to distribution of chain lengths, alginate solutions are not clearly Newtonian and behave 
as pseudo plastic fluid. When dissolved in pure water, their reduced viscosity is expected to 
increase very rapidly with dilution as observed by Focus and Straues. In the presence of 
supporting electrolyte rheological behavior of polyelectrolyte solution is known to depend on 
the ionic structure of the aqueous solvent, e.g. increasing the concentration of a strong 
electrolyte such as NaCl in the alginate solution up to 100mM was shown to reduce the 
solution viscosity due to the change in polymer conformation.  
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Chemical stability and degradation: Degradation of a Ca2+cross-linked alginate gel can 
occur by removal of the Ca2+ ions. This can be accomplished by the use of a chelating agent 
such as ethylene glycol-bis (b-amino ethyl ether)-N, N, N‟, N‟- tetra acetic acid (EGTA), 
lactate, citrate and phosphate or by a high concentration of ions such as Na + or Mg 2+. As 
Ca2+ ions are removed, the cross-linking in the gel decreases and the gels are destabilized. 
This can lead to leakage of entrapped material and solubilization of the high molecular 
weight alginate polymers. Alginate gels will also degrade and precipitate in a 0.1 M 
phosphate buffer solution and will completely dissolve in 0.1 M sodium citrate at pH 7.8. If 
Ca2+ is used in the cross-linking solution and phosphate is used as the dissolution medium, 
the dissolution medium will turn turbid due to the Ca dissociating from the polymer network 
and forming calcium phosphate precipitate. This phenomenon is more evident when a high 
guluronic content alginate is used. Low a-L- guluronic acid content alginate and lower 
molecular weight alginate are known to release encapsulated proteins at a much faster rate 
.Degradation of the gel can be prevented by storing the gel beads in a medium that contains 
free Ca2+ ions and to keep the Na+:Ca2+ ratio less than 25:1 for high a-L-guluronic acid 
alginates and 3:1 for low a L-guluronic acid alginates. Alginates have been reported to 
undergo proton catalyzed hydrolysis, which is dependent on time, pH, and temperature. A 
cross-linked alginate matrix delivery system when exposed to low pH can therefore undergo 
a reduction in alginate molecular weight, which results in faster degradation and release of a 
molecule when the gel is re-equilibrated in a neutral pH solution. Ability of alginate to form 
two types of gel depend on pH, i.e. an acid gel and an ionotropic gel, gives the polymer 
unique properties compared to neutral macromolecules. Alginate forms strong complexes 
with polycations including chitosan, polypeptides such as polylysine and synthetic polymers 
such as polyethylene mine. 
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METHOD OF PREPARATION [54, 55] 
A. Air atomization - Requires an extrusion device with a small orifice through which alginate 
solutions containing drug are forced. Beads of 5- to 200-µm particles can be produced. The 
size of beads can be controlled by either adjusting gas and liquid flow and operating pressure 
or distance between the orifice and the surface of the cross linking solution. 
 B. Coaxial bead generator- Coaxial air stream pulls droplets from a needle tip into gelling 
bath can produce spherical beads ranging in size down to around 400 µm.  
C. Dropping method-It is a Simple method Involves use of syringe with a needle or pipette. It 
is a most extensively utilized method for preparing the >500 µm particles. The size of beads 
formed is dependent on the size of needle used and viscosity of the alginate solution. 
D. Electrostatic bead generator-Electrostatic force pulls droplets from needle tip into gelling 
bath. By this method150- to 1000-µm particles can be produced. Bead size depends on the 
voltage and distance between the needle tip and the gelling bath, solution viscosity, flow rate 
of the solution as well as on needle diameter. 
E. Emulsification- Used only for stable drugs because it involves use of harsh chemical 
reagents to remove oil at the end of the process. Particles of size range 1- to 150-µm can be 
produced by this method. Size of micro beads produced depends on stirring speed and the 
rate of the addition of the cross-linking solution. 
F. Laminar jet- A device based on laminar jet breaks up induced by applying a sinusoidal 
frequency break up technique with defined amplitude to the nozzle. Normally 300-to 600 mm 
particles can be produced.  
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G. Mechanical cutting- Bead formation is achieved by means of a rotating cutting tool which 
cuts jet into uniform cylindrical segments, which form spherical beads due to surface tension 
while falling down into a gelling bath. 150-µm to 3-mm particles can be produced. 
H. Spinning disk atomization- Bead formation is achieved by specially designed spinning 
disk atomizer. It is suitable for 300- to 600-µm size particles. 
I. Vibrating nozzle technique - The encapsulation technique is based on a harmonically 
vibrating nozzle. By this method >200-µm particles can be produced. 
J. Complex Coacervation - Under specific conditions of polyion concentration, pH and ionic 
strength, the polyelectrolyte mixture can separate into two distinct phases; a dense coacervate 
phase which contains the micro beads and a dilute equilibrium phase. Oppositely charged 
complex poly-electrolytes have been commonly used. Optimum condition for maximum 
coacervate yield is pH of 3.9, an ionic strength of 1mM and a 0.15% w/v total polyion 
concentration. 
USEFUL PROPERTIES OFALGINATE AS MATRIX FOR CONTROLLED DRUG 
DELIVERY: 
Alginates have been widely used as tablet disintegrate, binding agent, viscosity 
modifying agent, as a stabilizer in disperse system in the production of suspension and 
emulsion and also as thickening agent in pharmaceutical industries. The most important 
advantage of using alginate as a matrix for Controlled release (CR) formulations is its 
biodegradability, because it is degraded and is absorbed by the body during and/or after drug 
release without any toxic effects. This allows bypass of surgical removal of the device. 
Hence, it can be a suitable matrix for sustained release of various drugs. Furthermore, 
because drug delivery can be controlled primarily through properties of polymer devices, CR 
is possible for conventional low molecular weight drugs as well as macromolecular drugs 
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including peptide hormones (e.g., insulin, growth hormone), polysaccharides (e.g., heparin), 
antibiotics, antigens, and enzymes. The release of drugs from alginate beads occurs mainly by 
diffusion through matrix and at certain pH due to erosion mechanism [51]. Release of drugs 
can be controlled by coating of matrix beads with sodium alginate. Sodium alginate has also 
been evaluated as release-controlling diluent in CR capsules. Several drugs have been 
incorporated into alginate matrices in a variety of forms (e.g., beads, micro spheres, films, 
and tablets), for CR therapies. The following properties of alginates have enabled it to be 
used as a most acceptable matrix for controlled drug delivery [57].  
(i) It is readily available and is relatively inexpensive.  
(ii) It contains ingredients that are accepted food additives.  
(iii) It is non-toxic when taken orally and also has a protective effecton mucous 
membranes of upper gastrointestinal tract.  
(iv) It is haemo-compatible and does not accumulate in any organ of the human body.  
(v) It is biodegradable so there is no need for surgical removal after the drug is 
exhausted.  
(vi) It can form hydro gels under mild conditions.  
(vii) It is water soluble so it eliminates use of noxious solvents during processing and 
hence stability, toxicological, and environmental problems associated with 
solvents can be minimized.  
(viii) It forms gel at room temperature and hence reduces chances of destroying activity 
of sensitive drugs at elevated temperatures.  
(ix) Soluble sodium alginate cross-linked with a variety of cross-linking agents, forms 
insoluble gel, which is used to delay release of some drugs.  
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(x) Flow properties of drugs with needlelike crystals (e.g., Sulfadiazine) can be 
improved by incorporating in alginate beads. This method of agglomeration also 
avoids polymorphic transformations as agglomerates are formed from drug 
dispersions. 
(xi) Beads formed are mechanically strong so they could be coated with enteric 
polymers to prepare enteric drug delivery systems.  
(xii) Adopted by European Pharmacopoeia.  
(xiii) The acceptable daily intake (ADI)for alginates are not specified which is the 
highest possible classification for food additives. The Food and Drug 
Administration has granted the generally recognized as safe (GRAS) status to 
alginates. The joint additive committee of the FAO and WHO experts has 
concluded that the daily permissible dose of sodium alginate 0-50 mg per Kg of 
human body weight. In 1990, the FAO and WHO removed the limitations for the 
daily consumption of alginates by man. 
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TAMARIND GUM – A NATURAL POLYMER 
Gums and Mucilages are polysaccharide complexes formed from sugar and uronic 
acid units. They can absorb large quantity of water and swell. They find wide range of 
pharmaceutical applications that includes their use as binder, disintegrates in tablets, 
emulsifiers, suspending agents, gelling agents and also used as sustaining agents in 
tablets.[58]Synthetic hydrophilic polymers are used more often than natural polymers, but 
because of cost associated with synthetic polymers, researchers are now showing interest in 
natural polymers (Non-Synthetic)such as gums. Tamarind (Tamarindus Indica L.) is amongst 
the most common and commercially important, large evergreen tree that grows abundantly in 
dry tracks of central and south Indian states, also in other south East Asian countries. The 
pulpy portion of fruit is mainly used asacidulant in Indian receipes. [59] Tamarind seeds or 
kernel is a byproduct of Tamarind pulp industry. 
Tamarind gum is obtained from endosperm of seeds of the tamarind tree, which is a 
seed gum with potential industrial application. Tamarind gum or tamarind kernel powder 
came into commercial production in 1943 as a replacement for starch in cotton sizing in 
Indian textile market. [60] It is also used in microbial production of lipids. It is also used in 
microbial production of lipids. It is an important sizing material for textile, a good creaming 
agent for concentration of rubber latex used as a soil stabilizer, a rich source of proteins and 
amino acids. Moreover tamarind kernel powder may also be used as afeed for cattle and 
pigs.6 It is also used as food ingredient. Currently purified and refined tamarind kernel 
powder is produced and permitted in Japan as a thickening, stabilizing and gelling agent in 
the food industry. Gum solutions of good adhesive strength from tamarind gum and sisal 
fibers were prepared which have potential industrial applications such as for false roofing and 
room portioning. Tamarind gum is used as a creamer for latex, in explosives, in boraxprinting 
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and paper manufacturing. It is also used as stabilizer in ice creams and as an emulsion textile 
paste. Thus tamarind gum is having applications in paper, food, textile industries. Recent 
year‟s research has been initiated on the use of tamarind gum in pharmaceutical and cosmetic 
applications. 
Chemical composition: 
The composition of tamarind kernel, the source of gum, resembles the cereals. With 
15.4 % to12.7 % protein, 3-7.5 % oil, 7-8.2 % crude fiber, 61-72.2 % non-fiber 
carbohydrates, 2.45-3.3 %ash; all were measured on a dry basis. Chemically tamarind kernel 
powder is highly branched carbohydrate polymer. Its backbone consists of D-glucose units 
joined with (1-4) b-linkages similar to that of cellulose. It consists of a main chain of b-D- (1-
4)-galactopyranosyl unit with aside chain of single xylopyranosyl unit attached to every 
second, third and fourth of D-glucopyranosylunit through a-D- (1-6) linkage (as shown in Fig 
1). One galactopyranosyl unit is attached to one of the xylopyranosyl units through b-D- (1-2) 
linkage. The exact sequential distribution of branches along the main chain is uncertain. 
Physical properties: 
Tamarind kernel powder disperses and hydrates quickly in cold water but does not 
reach maximum viscosity unless it is heated for 20-30 mins. The solution exhibits typical on-
Newtonian flow properties common to most other hydrocolloids. The functional property of 
tamarind kernel powder of protein concentrates was reported. The rheological properties of 
tamarind kernel powder suspension showed that suspension behaved like non-newtonian, 
pseudo plastic fluid with yield stresses and exhibited thyrotrophic characteristics. An 
increasing concentration produces increase in non-newtonian behavior as in consistency 
latex, yields stress and apparent viscosity.[61] 
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Pharmaceutical applications Tamarind seed polysaccharide 
Polysaccharide present in tamarind kernel powder is called as tamarind seed 
polysaccharide. Tamarind seed polysaccharide is having molecular weight 52350 units and 
monomer of glucose, galactose and xylose in molar ratio of 3:1:2.Various methods have been 
reported for isolation of tamarind seed polysaccharide from tamarind kernel powder. It is 
insoluble in organic solvents and dispersible in hot water to form a highly viscous gel such as 
mucilageneous solutions with a broad pH tolerance and adhesively. [62] In addition it is 
nontoxic and nonirritant with haemostatic activity. Recently tamarind seed polysaccharide is 
widely used for pharmaceutical applications. 
Pharmaceutical applications of tamarind seed polysaccharide: 
1. Binder in tablet dosage form 
Evaluations of tamarind seed polyose as a binder for tablet dosage forms was taken up 
for the weight granulation as well as direct compression methods. The results indicated that 
tamarind seed polyose could be used as binder for weight granulation and direct compression 
table ting methods. [63] 
2. In Ophthalmic drug delivery 
Tamarind seed polysaccharide is used for production of thickened ophthalmic 
solutions having apseudoplastic rheological behavior and mucoadhesive properties. Said 
solution is used as artificial tear and as a vehicle for sustained release ophthalmic drugs. The 
concentrations of tamarind seed polysaccharide preferably employed in ophthalmic 
preparations for use as artificial tears i.e. a products for replacing and stabilizing the natural 
tear fluid, particularly indicated for the treatment of eye syndrome are comprised between 
0.7-1.5% by weight. The concentrations of tamarind polysaccharides preferably employed in 
the production of vehicles (i.e. delivery system) for ophthalmic drugs having the function of 
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prolonging the prevalence time of medicaments at their site of actions are comprised between 
1 and 4 % by weight. [64] 
3. In sustained drug delivery 
It is used as potential polysaccharide having high drug holding capacity for sustained 
release of verapamil hydrochloride. The release pattern was found to be comparable with 
matrices of other polysaccharide polymers such as ethyl cellulose, hydroxyl ethyl cellulose 
and hydroxylpropylmethyl cellulose, as well as the commercially available sustained release 
tablets (isoptin SR). [65] It is also used as suitable polymer for sustained release formulations 
of low drug loading. Sustained release behaviors of both water soluble (acetaminophen, 
caffeine, theophylline and salicylic acid) and water insoluble (indomethacin) drugs on 
tamarind seed polysaccharide was examined. Studies showed that tamarind seed 
polysaccharide could be used for controlled release of both water-soluble and water insoluble 
drugs. Zero order release can be achieved taking sparingly soluble drugs like indomethacin 
from tamarind seed polysaccharide. 
The rate of release can be controlled by using suitable diluents like lactose and 
microcrystalline cellulose. For water-soluble drugs, the release amount can also be controlled 
by partially crosslinking the matrix. The extent of release can be varied by controlling the 
degree of crosslinking. The mechanism of release due to effect of diluents was found to be 
anomalous and due to crosslinking was found to be super case II. [66] 
4. In Ocular drug delivery 
Tamarind seed polysaccharide was used for ocular delivery of 0.3 % rufloxacin in the 
treatment of experimental pseudomonas aeruginosa and staphylococcus aureus keratitis in 
rabbits. The polysaccharide significantly increases the intraocular penetration of rufloxacin in 
both infected and uninfected eyes. Polysaccharide allows sustained reduction of S. Aureus in 
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cornea to be achieved even when the time interval between drug administrations was 
extended. The results suggested that tamarind seed polysaccharide prolongs the precorneal 
residence time of antibiotic and enhances the drug accumulation in the cornea, probably by 
reducing the washout of topically administered drugs. [67] 
5. In controlled release of spheroids 
Tamarind seed polysaccharide was used as release modifier for the preparation of 
diclofenacsodium spheroids using extrusion spheronization technique with microcrystalline 
cellulose as spheronization enhancer. It was found that release was sustained over a period of 
7.5 hour. A credible correlation was obtained amongst swelling index, viscosity, and surface 
roughness of the polysaccharide particles and in vitro dissolution profile of spheroids. In the 
comparative bioavailability study the developed spheroids have able to sustained drug release 
and also was found to improve the extent of absorption and bioavailability of drug. [67] 
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CHITOSAN & ITS DERIVATIVES: RECENT INNOVATIONS 
Over the last few decades, the global environmental problem has attracted significant 
awareness of the research community and policymakers for the development of polymeric 
materials which are degradable in a natural environment. The production of biodegradable 
polymers which are decomposed by microorganisms and photodegradable polymers that are 
decomposed by sunlight is a priority among researchers.  An ideal biodegradable polymeric 
material is one which after being disposed of can be recycled many times before promptly 
being decomposed by microorganisms or sunlight providing carbon dioxide and water. 
Chitosan is such a type of polymer which is degradable in natural environment. 
Chitosan is a poly cationic naturally occurring bio-degradable, non-toxic, non-
allergenic biopolysaccharide derived from chitin which is found in abundance in nature[68]. It 
contains more than 5000 glucosamine units and is obtained commercially from shrimp and 
crab shell containing chitin which is an N- acetyl glucosamine polymer. The N- acetyl 
glucosamine gets converted in to glucosamine units by alkaline de-acetylation with NaOH 
(with 40-50% conc.).Chitosan is considered as most promising materials for future 
applications on account of its excellent biodegradability, biocompatibility, non-toxicity, 
antimicrobial activity, and its economic advantages. The chemical structure of chitin is made 
up of linear monomeric units of 2- acetamido-2-deoxy- D-glucopyranose attached through ȕ-
(1-4) linkages. 
SOURCES AND EXTRACTION OF CHITOSAN FROM RAW MATERIALS: 
Chitin, the main source of chitosan is widely distributed both in the animal and the 
plant kingdom. Henry Braconnot (1780–1855) was the first who isolated chitin from 
mushrooms in 1811 about two centuries ago. It was the first polysaccharide which was 
identified by man preceding by cellulose about 30 years. The main sources of chitin are 
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Fungi, Algae, Echiruda, Annelida (Segmented worms), Mollusca, Cnidaria (jellyfish), 
Aschelminthes (roundworm), Entoprocta, Bryozoa (Moss or lace animals, Phoronida (Horse 
shoe worms), Brachiopoda (Lamp shells), Arthropoda and Ponogophora. Chitin; also the 
major component of arthropods tendons, exoskeletons and the linings of their digestive, 
excretory and respiratory systems and insect‟s external structure as well as of some fungi. 
It is also found in the iridophores (reflective material) of both eyes and epidermis of 
cephalopods and arthropods of phylum Mollusca and the epidermal cuticle of the vertebrates. 
Epidermal cuticle of Paralipophrystrigloides is also chitinous in nature. 
Chitin occurs in three polymorphic solid state forms designated as α, ȕ, and Ȗ chitin 
which differ in their degree of hydration, size of unit cell, and number of chitin chains per 
unit cell. Chains of chitin may be arranged in a tightly compacted crystalline structure of ant 
parallel sheets and extensive intermolecular hydrogen bonding (α-chitin), in a more mobile 
allomorph of parallel sheets (ȕ-chitin), or a combination of both (Ȗ-chitin) (Fig. 3).α-Chitin is 
most abundant and is found in shellfish exoskeletons and fungal cell walls. ȕ-Chitin is mainly 
found in squid pens and diatoms while Ȗ-chitin may be predominantly found in squid and 
cuttlefish stomach lining.[69,70] 
 
   α-chitin  ȕ-chitin       Ȗ-chitin 
FIG NO.3 SHOWING α, ȕ AND Ȗ-CHITIN 
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Chitosan is commercially interesting compounds because of its high nitrogen content 
(as compared to synthetically substituted cellulose) which makes chitosan a very useful 
chelating agent. The elemental composition of Chitosan [71] is described in Table 1. 
TABLE NO. 1 ELEMENTAL COMPOSITION OF CHITOSAN 
SR. NO ELEMENTS % IN CHITOSAN 
1. Carbon 44.11 
2. Nitrogen 7.97 
3. Hydrogen 6.84 
 
Both chitin and chitosan have unusual multifunctional properties, including high 
tensile strength, bioactivity, biodegradability, biocompatibility, non-toxicity and non-antigen 
city which made them possible to be used in many applications. 
Furthermore, the chemical modifications of the three reactive functional groups of 
chitosan had increased the applications of chitosan in different fields. Chitosan has three 
reactive groups, which is primary (C-6) and secondary (C-3) hydroxyl groups (Fig. 4) on 
each repeat unit and the amino (C-2) group on each deactivated unit. The presence of these 
reactive functional groups which may readily subject to chemical modifications to alter 
physico-mechanical properties of chitosan formulates it wonderful material for different 
purposed applications. 
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Fig NO: 4 - SHOWING STRUCTURES OF (a) CHITOSAN AND (b) CELLULOSE 
PROPERTIES OF CHITOSAN:[72-74] 
Chitosan has attracted increasing attention in the past decade due to its unique 
properties including non-toxicity, biocompatibility, and biodegradation including many 
others discussed in the pending text. One; among the notable and much exploited is; its 
antimicrobial commotion inhibiting the growth of a wide variety of fungi, yeasts and bacteria 
making it beneficial for use in the field of biomedicine. 
It can also bind toxic metal ions, beneficial for use in air cleaning and water 
purification applications. These properties arise as a result of protonation of NH2 groups on 
the chitosan backbone. Structurally, chitosan is a linear-chain copolymer composed of D-
glucosamine and N-acetyl-D-glucosamine being obtained by the partial deacetylation of 
chitin. 
The structure of chitosan is very much similar to that of cellulose and is the second 
most abundant natural polymer after cellulose. The solubility, biodegradability and reactivity 
of chitosan and adsorption of substrates depend on the extent of protonated amino groups in 
the chain of polymer. Chitosan is incapable of being dissolved in water, organic solvents and 
aqueous bases however get dissolved after stirring in acetic, nitric, hydrochloric, perchloric 
and phosphoric acids. The amino group of chitosan is not protonated in alkaline or neutral 
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medium and therefore it is insoluble in water; while in acidic pH it gets the resultant soluble 
protonated polysaccharide. 
Chitosan forms water-soluble salts with inorganic and organic acids including 
glyoxylate, pyruvate, tartarate, malate, malonate, citrate, acetate, lactate, glycolate, and 
ascorbate. Inherent chitosan becomes soluble in organic acids when the pH of the solution is 
less than 6.5. The water-soluble salts of chitosan may well be formed by neutralization with 
acids such as lactic acid, hydrochloric acid, acetic acid, or formic acid. 
There are various other factors which may affect the physicochemical properties of 
chitosan enabling the researchers to formulate different grades of chitosan which differ 
primarily in molecular weight, crystallinity and degree of deacetylation. During its processing 
from raw material, different conditions such as type and concentration of reagents, time and 
temperature employed can affect the physical characteristics of chitosan product. Its 
molecular weight also depends on solubility, viscosity, elasticity and tears strength. 
 
FIG. NO: 5 - FACTORS AFFECTING PHYSICO-CHEMICAL PROPERTIES OF 
CHITOSAN 
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Chitosan is a pseudo plastic material and is an excellent viscosity-enhancing agent in 
acidic environments. The viscosity of chitosan solution is affected by the molecular weight, 
degree of deacetylation, pH, ionic strength, concentration, and the temperature. Generally, 
there is a decrease in the viscosity of the solution on the increase in temperature and increases 
with an increase in chitosan concentration. The effect of the pH on the viscosity depends on 
particular type of acid used. 
The characteristics of chitosan required for a particular application are dependent 
upon the degree of acetylating (DA) and its molecular weight. The degree of deacetylation of 
molecular chain of chitin; however, an extrinsic property; hence increased by increasing the 
temperature or strength of the alkaline solution. The viscosity of chitosan also influences the 
biological properties such as wound-healing properties as well as biodegradation by 
lysozyme. 
As the Chitosan is hydrophilic in nature, therefore it has the ability to form gels at 
acidic pH. This type of gels can be used as a slow-release drug-delivery system. The 
solubility of Chitosan can be decreased by cross-linking it with covalent bonds using 
glutraldehyde. The swelling property of the chitosan decreases with an increase in the 
concentration of cross-linking agent. 
The various chemical and biological properties of chitosan are as follows:[75-81] 
 Natural, linear polyamine with reactive amino and hydroxyl groups. 
 Chelates with transitional metal ions. 
 Biocompatible and biodegradable to normal body constituents. 
 Non-toxic and safe to use. 
 Binds to microbial and mammalian cells. 
 Haemostatic, fungi static and spermicidal agent. 
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 Antitumor and anti-inflammatory agent. 
 Accelerate bone regeneration. 
 Immuno adjuvant and drug delivery agent. 
DERIVATIVES OF CHITOSAN: 
The use of chitosan has been postulated in numerous areas of biopharmaceutical 
research such as mucoadhesion, permeation enhancement, vaccine technology, gene therapy 
and wound healing. Recent applications of chitosan are in ophthalmic, nasal, sublingual, 
buccal, periodontal, gastrointestinal, colon-specific, vaginal, transdermal drug delivery and 
mucosal-vaccine and gene carrier. It can also be used in the pharmaceutical industry in direct 
tablet compression, as tablet disintegrant, for the production of controlled release solid 
dosage form or for the improvement of drug dissolution Chitosan derivatives were developed 
to improve not only biological activities but also water-soluble property, because the water-
insoluble property was a major limiting factor for industrial application in spite of its unique 
biological aspects. 
The improvement of structural properties of chitosan for a particular application can 
be easily brought about by chemical modification. Fortunately, chitosan is amenable to 
chemical modifications due to having of hydroxyl, acetamido and amine functional groups. 
For that reason, chemical modifications would not change the fundamental skeleton of 
chitosan and would keep the original physicochemical and biochemical properties while 
bringing new or improved properties. The various derivatives of chitosan developed by 
different researchers during the recent years are briefly described as: 
Quaternarized water-soluble derivatives of chitosan:[82] 
Chitosan and its derivatives; having solubilities in pH values of lower than 6.0 are not 
desired for their use in cosmetics, medicine and food relevance. In order to improve its 
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solubility at neutral pH, firstly it is derivatized with substituents containing quaternary amino 
group, caboxymethylation and then sulfonation by adding strongly hydrophilic substituent. 
The simplest derivative of chitosan is the trim ethyl ammonium salt. The treatment of 
chitosan in N-methyl-2 pyrrolidone containing sodium iodide and methyl iodide with 
chloride ion in presence of sodium hydroxide resulting into the trim ethyl ammonium salt of 
chitosan having high degree of substitution. The anionic changes of iodide with chloride ions 
are necessary for stabilization resulting in water soluble product at neutral pH. 
Chitosan-triphosphate nanoparticles: 
Ionotropic gelation methods are the most common to achieve a pharmaceutical 
product with desired characteristics. Super-paramagnetic iron oxide nanoparticles (SPIONPs) 
were encapsulated by Sanjaia, et al. at various concentrations within chitosan-triphosphate 
(SPIONPs-CS) using the ionotropic gelation method. Ionotropic gelation is based on the 
ability of polyelectrolytes counter ions to cross link to form hydrogels. Naturally occurring 
polysaccharides such as chitosan which have relevant use as biopolymers has been increased 
in the novel area such as hydrogel sustained release formulation, thus providing an eco-
friendly pharmaceutical product development process. 
The dispersion ability of CS nanoparticles get enhanced by encapsulation of SPIONPs 
in aqueous solution, with all particles being lower than 130 nm in size and having high 
positive surface charge. The SPIONPs-CS nanoparticles exhibited super-paramagnetic 
properties at room temperature. These SPIONPs-CS nanoparticles can be applied as tissue-
specific MRI contrast agents. This system has advantages over other MR agents in that 
preparation is simple, and can be undertaken under mild conditions. Furthermore, SPIONPs 
CS nanoparticles showed low cytotoxicity against skin fibroblast cells at proper 
concentrations, and excellent stability for over prolonged periods. These SPIONPs-CS 
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nanoparticles have the potential to be utilized as a MR contrast agents in tissue environments 
in the human body. 
Bentonite/Chitosan Beads[83] 
Bentonite is a common group of clay minerals, which is a hydrous aluminium silicate, 
and it has been reported as an economical material for adsorption of fluoride from water. 
Chitosan has been cited as an excellent material for defluoridation from water. However, raw 
chitosan used in the form of flakes or powder is unstable and the adsorption capacity reported 
is minimum, thus, it is necessary to modify chitosan physically or chemically in order to 
improve its practical uses. 
Recently Zhang et al. has synthesized a new adsorbent namely bentonite/chitosan 
beads for its defluoridation efficiency. Bentonite was activated and the beads were prepared 
by using the inverse suspension polymerization method. The adsorption of fluoride onto the 
adsorbent followed Freundlich isotherm model and pseudo-second order kinetic model. The 
fluoride loaded adsorbent could be regenerated using sodium hydroxide. Bentonite/chitosan 
beads are of low-cost, effective and reusable adsorbent for adsorption of fluoride. 
Chitosan based hydrogels: [83-84] 
Hydrogel (also called aquagel) is a network of polymer chains that are hydrophilic, 
sometimes found as a colloidal gel in which water is the dispersion medium. Hydrogels are 
highly absorbent (they can contain over 99.9% water) natural or synthetic polymers. 
Hydrogels also possess a degree of flexibility very similar to natural tissue, due to their 
significant water content. 
Hydrogels based on covalently cross-linked chitosan can be divided into three types 
with respect to their structure: chitosan cross-linked with itself (Fig. 6a), hybrid polymer 
networks (HPN) (Fig. 6b) and semi- or full-interpenetrating polymer networks (IPN) (Fig. 
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6c). The simplest structure presented here is chitosan cross-linked with it. As represented in 
(Fig. 6a),cross linking involves two structural units that may or may not belong to the same 
chitosan polymeric chain. 
The final structure of such a hydrogel could be considered as a cross-linked gel 
network dissolved in a second entangled network formed by chitosan chains of restricted 
mobility. In hydrogels formed by a HPN, the cross linking reaction occurs between a 
structural unit of a chitosan chain and a structural unit of a polymeric chain of another type 
(Fig. 6b), even if cross linking of two structural units of the same type and/or belonging to the 
same polymeric chain cannot be excluded. 
Finally, semi- or full- IPNs contain a non-reacting polymer added to the chitosan 
solution before cross linking. This leads to the formation of a cross-linked chitosan network 
in which the non-reacting polymer is entrapped (semi-IPN). It is also possible to further 
crosslink this additional polymer in order to have two entangled cross-linked networks 
forming a full-IPN, whose microstructure and properties can be quite different from its 
corresponding semi-IPN. 
Semi and full interpenetrating polymer network (IPN) type hydrogels were prepared 
by free radical in situ polymerization of methacrylic acid in presence of chitosan using N, N 
methylene-bis-acrylamide (MBA) and glutaraldehyde (for full IPN) as cross-linker. Several 
semi and full IPN type hydrogels were prepared by varying initiator and cross-linker 
concentration and also monomer to chitosan mass ratio. These hydrogels were characterized 
and used for removal of methyl violet and congo red dye from water.  
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FIG. NO.6- STRUCTURE OF CHITOSAN HYDROGELS FORMED BY (A) CHITOSAN 
CROSS-LINKED WITH ITSELF; (B) HYBRID POLYMER NETWORK; (C) SEMI-
INTERPENETRATING NETWORK; (D) IONIC CROSSLINKING 
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CAPECITABINE IN THE MANAGEMENT OFCOLORECTAL 
CANCER 
5-Fluorouracil (5-FU) was initially introduced over 40 years ago and has remained a 
mainstay in treatment regimens for colorectal cancer (CRC) since that time, both alone and in 
combination with other agents. Its impact on cancer care has been substantial as CRC is the 
third most commonly diagnosed cancer in the United States with 142,570 new cases in 2009, 
and it is the third leading cause of cancer death in both men and women with a combined 
51,370 fatalities in the same year. [93]Despite the importance of 5-FU to cancer care, its short 
half-life, requirement for a central line, and the need for continuous infusions led researchers 
to design an oral formulation of the drug. In June 2005, capecitabine (Xeloda®; Hoffman-
LaRoche, Nutley, NJ) was approved by the Food and Drug Administration (FDA) as an oral 
prodrug of 5-FU for use as monotherapy in the adjuvant setting when treating Dukes‟ stage C 
CRC. 
Capecitabine has a number of advantages over traditional 5-FU. After absorption 
across the digestive tract, it is converted to 5-FU through three sequential enzymatic 
reactions. The final enzyme in the pathway, thymidine phosphorylase (TP), is believed to be 
present at disproportionately high levels in tumor tissue, which is said to increase both the 
efficacy and tolerability of the agent through targeted delivery. Its oral administration 
simplifies care, frequently precluding the need for central venous access or infusion pumps. 
As a result, capecitabine is increasingly used for off-label indications in CRC, including 
monotherapy in the advanced or metastatic setting, combination therapy in conjunction with 
oxaliplatin in the advanced or metastatic setting, and with concurrent radiation for the 
neoadjuvant treatment of rectal cancer.[86] As off-label use of capecitabine increases, it 
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becomes even more important to understand the efficacy and tolerability across settings, 
which support its utilization in order to ensure the appropriate treatment of patients. 
The purpose of this introducing is, therefore, to provide an overview of capecitabine‟s 
mechanism of action and rate of adverse events as well as an analysis of the evidence 
supporting its use in the settings outlined above. In addition, this article will highlight the 
regional differences in tolerance that affect dosing decisions and the evidence behind its use 
in the elderly, which remains an area of controversy. Finally, the economic literature will be 
discussed. The decision to prescribe capecitabine is a complex one; however, increasing 
evidence is emerging to guide clinicians. 
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1. Kathiravan P et al., (2015), have formulated and evaluated Colon Specific Drug 
Delivery System of Capecitabine Containing Polymer Coated Capsule Dosage Form; a 
polymer surface encompassed capsule dosage form of capecitabine was investigated and 
personalized for colon-targeted delivery of drugs. The sandwich replica of the system was 
designed by imparting the essences of time-release function and a pH-sensing function to 
a hard gelatin capsule. The technical traits of the system are fabricated to contain an 
organic acid together with an active ingredient in a capsule coated with a three-layered 
film consisting of an acid-soluble polymer, a water-soluble polymer, and an enteric 
polymer. In order to prioritize the suitable formulation, various formulation factors were 
investigated through a series of in vitro dissolution studies. The results are compiled as: 
(1) various organic acids can be used for this system invariably; (2) a predictable timed-
release mechanism of a drug can be attained by tailoring the thickness of the Eudragit E 
100 layer; and (3) the outer enteric coating with CMEC lends acceptable acid- 
resistibility. The result out comes postulate and suggests that this approach can provide a 
beneficial and practical means for colon-targeted delivery of drugs. This engineered 
structure has a proven benefit in various fronts for the end organ (colon), getting optimum 
concentration of drug to cause the therapeutic improvisation in the segment of 
malignancy and its associated risks within it.[87] 
2. Hetal K Patel, et al., (2008), have designed the Characterization of calcium alginate 
beads of  5-fluorouracil for colon delivery-  A multiparticulate system combining pH-
sensitive property and specific biodegradability for colon targeted delivery of 5-
fluorouracil (5-FU) was examined. The purpose of this study was to prepare and evaluate 
the colon-specific alginate beads of 5-FU for the treatment of colon cancer. Calcium 
alginate beads were prepared by extruding 5-FU loaded alginate solution to calcium 
chloride solution, and gelled spheres were formed instantaneously by ionotropic gelation 
reaction using different ratios of FU and alginate, alginate and calcium chloride, stirring 
speeds (500-1500 rpm), and reaction time. The core beads were coated with Eudragit S-
100 to prevent drug release in the stomach and provide controlled dissolution of enteric 
coat in the small intestine and maximum drug release in the colon. Morphology and 
surface characteristics of the formulation were determined by scanning electron 
microscopy. In vitro drug release studies were performed in conditions simulating 
stomach to colon transit. No significant release was observed at acidic pH, however, 
when it reached the pH where Eudragit S-100 starts to dissolve, drug release was 
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observed. Also, release of drug was found to be higher in presence of rat caecal 
content.[88] 
3. Mohamad Anuar Kamaruddin, et al., (2014), was formulated preparation and 
characterization of alginate beads by drop weight, the preparation and characterization of 
macro alginate beads are always associated with appropriate techniques involving precise 
measurement of shape, size, volume and density of the products. Depending on the type 
of application, encapsulation of macro alginate beads can be accomplished by various 
techniques including chemical, ionotropic, physical and mechanical methods. This work 
describes a method for preparing macro alginate beads through drop weight. The macro 
beads (2.85–3.85 mm) were prepared via different concentrations of alginate (0.5, 1.0, 1.5 
and 2.0 g/L), dripping tip size (0.04–0.14 cm) and immersion into a predetermined 
concentration of calcium chloride (CaCl2) bath. A custom made dripping vessel fabricated 
from acrylic plastic, connected to an adjustable dripping clamp was used to simulate the 
dripping process of the molten alginate at different tip sizes. It was observed that at 
different dripping tips, the correction factor for the alginate slurry was found in the range 
of 0.73–0.83. Meanwhile, the lost factor, KLF was observed at 0.93–2.3 and the 
shrinkage factors were limited to 2.00% from the overall distributed data. It was 
concluded that liquid properties had no effect on the liquid lost factor. The bead size 
prediction for different concentrations of alginate solution was compared to the 
experimental data. Subsequently, it was concluded that increasing the tip size caused the 
bead size to deviate almost 20% when compared to the experimental and predicted 
values, respectively. [89] 
4. Lorena Segale et al., (2016), developed Calcium Alginate and Calcium Alginate-
Chitosan Beads Containing Celecoxib Solubilized in a Self-Emulsifying Phase - In this 
work alginate and alginate-chitosan beads containing celecoxib Solubilized into a self-
emulsifying phase were developed in order to obtain a drug delivery system for oral 
administration, able to delay the drug release in acidic environment and to promote it in 
the intestinal compartment. The rationale of this work was linked to the desire to improve 
celecoxib therapeutic effectiveness reducing its gastric adverse effects and to favor its use 
in the prophylaxis of colon cancer and as adjuvant in the therapy of familial polyposis. 
The systems were prepared by ionotropic gelation using needles with different diameters 
(400 and 600 𝜇m). Morphology, particle size, swelling behavior, and in vitro drug release 
performance of the beads in aqueous media with different pH were investigated. The 
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experimental results demonstrated that the presence of chitosan in the formulation caused 
an increase of the mechanical resistance of the bead structure and, as a consequence, a 
limitation of the bead swelling ability and a decrease of the drug release rate at neutral 
pH. Alginate-chitosan beads could be a good tool to guarantee a celecoxib colon 
delivery.[90] 
5. Bera H et al., (2015), designed Alginate gel-coated oil-entrapped alginate-tamarind gum-
magnesium stearate buoyant beads of risperidone. A novel alginate gel-coated oil-
entrapped calcium-alginate-tamarind gum (TG)-magnesium stearate (MS) composite 
floating beads was developed for intragastricrisperidone delivery with a view to 
improving its oral bioavailability. The TG-blended alginate core beads containing olive 
oil and MS as low-density materials were accomplished by ionotropic gelation technique. 
Effects of polymer-blend ratio (sodium alginate:TG) and cross linker (CaCl2) 
concentration on drug entrapment efficiency (DEE, %) and cumulative drug release after 
8 h (Q8h, %) were studied to optimize the core beads by a 3(2) factorial design. The 
optimized beads (F-O) exhibited DEE of 75.19±0.75% and Q8h of 78.04±0.38% with 
minimum errors in prediction. The alginate gel-coated optimized beads displayed superior 
buoyancy and sustained drug release property. The drug release profiles of the drug-
loaded uncoated and coated beads were best fitted in Higuchi kinetic model with Fickian 
and anomalous diffusion driven mechanisms, respectively. The optimized beads yielded a 
notable sustained drug release profile as compared to marketed immediate release 
preparation. The uncoated and coated Ca-alginate-TG-MS beads were also characterized 
by SEM, FTIR and P-XRD analyses. Thus, the newly developed alginate-gel coated oil-
entrapped alginate-TG-MS composite beads are suitable for intragastric delivery of 
risperidone over a prolonged period of time. [91] 
6. Ji Zhang et al., (2008), was prepared and Characterization of Tamarind Gum/Sodium 
Alginate Composite Gel Beads. A two-step preparation and the characterization of 
composite gel beads of tamarind gum (2.0 wt%) and sodium alginate (0.6 wt%) as 
spherically well-shaped forms are reported. In the first step, the prepared solution 
containing tamarind gum and sodium alginate was extruded as small drops by means of 
syringe into a stirred calcium chloride (CaCl2 , 3.0 wt%) at 4ºC and then in the second 
step the beads were soaked in solidified agent solution (Na
 2 B4O7 , 2.0 Wt%). Thus, we 
obtained composite gel beads with diameter range between 2 and 3 mm. We have 
demonstrated the properties of the composite beads, such as morphological, thermal 
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stability and functional groups characterized by different techniques (i.e., SEM, DSC, and 
FTIR). The swelling behaviour in response to pH variation as well as the mechanical 
strength of the composite gel beads are examined and reported. The results have 
demonstrated that the composite gel beads not only have the advantages of rather rough 
surface, three-dimensionally network structure, and high anti-acid and anti-alkali 
properties, they are not prone to breakage under load. The composite gel beads prepared 
are potentially useful as polymeric carriers or supports in biotechnology and biochemistry 
applications.[92] 
 
7. Seong-In Park et al., (2013), formulated Glutaraldehyde-crosslinked chitosan beads for 
sorptive separation of Au(III) and Pd(II): Opening a way to design reduction-coupled 
selectivity-tunable sorbents for separation of precious metals- Glutaraldehyde (GA)-cross 
linked chitosan beads (GA-CS) are prepared with coagulating solution containing sodium 
tripolyphosphate and GA, and used for the adsorption of metals from binary-metal 
solution Au(III) and Pd(II). GA-CS exhibited selective sorption of Au(III) in the Au(III)–
Pd(II) mixture. X-ray diffraction analyses showed that Au(III) was reduced to Au(0) 
following sorption, while Pd(II) was present as unreduced divalent form. Increased GA 
led to more selectivity toward Au(III), indicating that Au(III) selectivity is attributed to 
reduction-couple sorption of Au(III) with a reducing agent GA. Furthermore, a 2-step 
desorption process enabled selective recovery of Pd and Au using 5 M HCl and 0.5 M 
thiourea–1 M HCl, respectively, leading to pure Pd(II) and Au(III)-enriched solutions. 
This finding may open a new way to design reduction-coupled selectivity-tunable metal 
sorbents by combination of redox potentials of metal ions and reducing agents. [93] 
8. Abeer Bashir et al., (2016), extracted and characterized xyloglucan (tamarind seed 
polysaccharide) as pharmaceutical excipient- Recent study includes extraction and 
characterization of the xyloglucan from tamarind (Tamarindus indica) seed 
polysaccharide as a pharmaceutical agent. Tamarind seed polysaccharide was obtained by 
water based extraction in Soxhlet apparatus. For characterization of the extracted 
tamarind seed polysaccharide phytochemical screening was done and micromeritic 
properties, flow behavior and swelling index were determined. It was also found that 
extracted tamarind seed polysaccharide had good flow properties and pH was 6.4, this 
showed that it can be used in dosage form, without any irritation. Mucoadhesive nature of 
extracted tamarind seed polysaccharide was also evaluated by texture analyzer in 
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different concentration range (0.5% and 1%, w/v) and results revealed that it shows 
concentration based mucoadhesive strength. It can be concluded that tamarind derived 
seed polysaccharide (xyloglucan) can be used as pharmaceutical agent to prepare 
different types of formulations. [94] 
9. Thulasi V Menon et al., (2013),formulated and evaluated Sustained Release Sodium 
alginate micro beads of carvedilol. The main aim of the study is to formulate Carvedilol 
loaded micro beads of sodium alginate using gelatin and pectin as release modifiers by 
ionotropic gelation method. The micro beads were prepared by varying the concentration 
of sodium alginate, gelatin and pectin. The drug-polymer compatibility was studied by 
FTIR studies. The prepared micro beads were evaluated for swelling ratio, particle size, 
drug entrapment, Scanning electron microscopy (SEM), bio adhesion study and inviter 
release study. Particle size distribution of both placebo and drug loaded formulations 
were measured by an optical microscope and particle size of optimized beads was 
determined by SEM. No significant drug-polymer interactions were observed in FT-IR 
studies. In-vitro drug release profile of Carvedilol micro beads was examined in pH 1.2 N 
Hydrochloric acid for first 2 hours followed by phosphate buffer pH 7.4 for remaining 
time. The in vitro wash-off test indicated that the sodium alginate micro beads had good 
mucoadhesive properties. The formulated beads had shown higher entrapment efficiency, 
drug loading, low particle size and moisture content. The formulation F3 released 
carvedilol for longer duration (24 hours) and showed better mucoadhesion. [95] 
10. A. Kramar et al., (2002), designed Statistical optimization of diclofenac sustained 
release pellets coated with polymethacrylic films - The objective of the present study was 
to evaluate three formulation parameters for the application of polymethacrylic films 
from aqueous dispersions in order to obtain multiparticulate sustained release of 
diclofenac sodium. Film coating of pellet cores was performed in a laboratory fluid bed 
apparatus. The chosen independent variables, i.e. the concentration of plasticizer (triethyl 
citrate), methacrylate polymers ratio (Eudragit RS:Eudragit RL) and the quantity of 
coating dispersion were optimized with a three-factor, three-level Box-Behnken design. 
The chosen dependent variables were cumulative percentage values of diclofenac 
dissolved in 3, 4 and 6 h. Based on the experimental design, different diclofenac release 
profiles were obtained. Response surface plots were used to relate the dependent and the 
independent variables. The optimization procedure generated an optimum of 40% release 
in 3 h. The levels of plasticizer concentration, quantity of coating dispersion and polymer 
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to polymer ratio (Eudragit RS: Eudragit RL) were 25% w/w, 400 g and 3/1, respectively. 
The optimized formulation prepared according to computer-determined levels provided a 
release profile, which was close to the predicted values. We also studied thermal and 
surface characteristics of the polymethacrylic films to understand the influence of 
plasticizer concentration on the drug release from the pellets. [96] 
11. Hong Wu et al., (2005), Prepared and Drug Release Characteristics of Pingyangmycin- 
Loaded Dextran Cross-Linked Gelatin Microspheres for Embolization Therapy - Gelatin 
microspheres (GMs) containing Pingyangmycin hydrochloride were prepared for the 
interventional embolization by a double-phase emulsified thermal gelation method using 
oxidized dextran (ox-dex) as the cross-linking agent. The average diameter of the 
microspheres was 82 µm with 74% ranging from 50–200 µm. Drug content and the 
characteristics of drug release in vitro and in vivo were evaluated using UV-spectroscopy 
and HPLC, respectively. The prepared microspheres showed a rather high percentage of 
encapsulation ranging from 85 to 88% and drug content at 7.2%. The results of in vitro 
experiments showed that about 65.5% of the total amount of the encapsulated drug was 
released after 6 h at 37°C. Experiments conducted through artery perfusion and artery 
embolization in rabbits revealed that the local drug concentration was significantly higher 
than the systemic blood– drug concentration, with a high level of local drug concentration 
maintained for more than 120 min after artery embolization with the Pingyangmycin-
loaded ox-dex-GMs. The results indicated that the external carotid artery embolization 
with Pingyangmycin-loaded ox-dex- GMs at reduced dosages prolonged the local drug 
concentration at a higher level, and could achieve the purpose of a localized targeting 
tumor therapy. Compared with other embolization materials, ox-dex-GMs are an 
excellent alternative interventional embolization material for the treatment of head and 
neck tumors. [97] 
12. TaeHee Kim et al., (2005), Performed Drug release from xyloglucan beads coated with 
Eudragit for oral drug delivery Xyloglucan (XG), which exhibits thermal sol to gel 
transition, non-toxicity, and low gelation concentration, is of interest in the development 
of sustained release carriers for drug delivery. Drug-loaded XG beads were prepared by 
extruding drop wise a dispersion of indomethacin in aqueous XG solution (2 wt.-%) 
through a syringe into corn oil. Enteric coating of XG bead was performed using Eudragit 
L 100 to improve the stability of XG bead in gastrointestinal (GI) track and to achieve 
gastro resistant drug release. Release behavior of indomethacin from XG beads in vitro 
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was investigated as a function of loading content of drug, pH of release medium, and 
concentration of coating agent. Adhesive force of XG was also measured using the tensile 
test. Uniform-sized spherical beads with particle diameters ranging from 692 ± 30 to 819 
± 50 μm were obtained. The effect of drug content on the release of indomethacin from 
XG beads depended on the medium pH. Release of indomethacin from XG beads was 
retarded by coating with Eudragit and increased rapidly with the change in medium pH 
from 1.2 to 7.4. Adhesive force of XG was stronger than that of Carbopol 943 P, a well-
known commercial mucoadhesive polymer, in wet state. Results indicate the enteric-
coated XG beads may be suitable as a carrier for oral drug delivery of irritant drug in the 
stomach. [98] 
13. Praveen Kumar Gaur et al., (2013), was developed and optimized gastro-retentive 
mucoadhesive microspheres of gabapentin by Box– Behnken design Context: Gabapentin 
follows saturation kinetics for absorption because of carrier-mediated transport and 
narrow absorption window in stomach. There is need to develop a gastro-retentive 
formulation to maximize the absorption without crossing the saturation threshold for 
absorption. Objective: The aim was to develop a gastro-retentive formulation of 
gabapentin to increase the fraction of drug absorbed in stomach. Materials and methods: 
Sodium alginate and sodium Carboxymethylcellulose were used to formulate the 
microsphere by ionotropic gelation with calcium chloride. The formulation was optimized 
using a three-factor, three-level Box – Behnken design. Results: The particle size varied 
from 559.50 to 801.10 m, entrapment efficiency from 61.29 to 81.00% and in vitro 
release from 69.40 to 83.70%. The optimized formulation was found using point 
prediction, and formulation OF-3 showed optimum results at 608.21 m size, 79.65% 
entrapment efficiency and 82.72% drug release and 81% mucoadhesion up to 10 h. The 
drug release was controlled for more than 12 h. Discussion: The particle size was most 
influenced by sodium alginate while entrapment efficiency and drug release depended 
upon both polymers. The release followed Higuchi model. Conclusion: Gastro-retentive 
formulation was successfully optimized by a three-factor, three level Box – Behnken 
design and found to be useful.[99] 
14. UbaidullaUdhumansha et al., (2008), Optimized Chitosan Succinate and Chitosan 
Phthalate Microspheres for Oral Delivery of Insulin using Response Surface... In the 
present study, a Box-Behnken experimental design was employed to statistically optimize 
the formulation parameters of chitosan phthalate and chitosan succinate microspheres 
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preparation. These microspheres can be useful for oral insulin delivery system. The 
effects of three parameters namely polymer concentration, stirring speed and cross linking 
agent were studied. The fitted mathematical model allowed us to plot response surfaces 
curves and to determine optimal preparation conditions. Results clearly indicated that the 
crosslinking agent was the main factor influencing the insulin loading and releasing. The 
in vitro results indicated that chitosan succinate microspheres need high amount of 
crosslinking agent to control initial burst release compared to chitosan phthalate 
microspheres. The reason may be attributed that chitosan succinate is more hydrophilic 
than chitosan phthalate. The relative pharmacological efficacy for chitosan phthalate and 
chitosan succinate microspheres (18.66, 3.84%, 16.24, 4%) was almost three-fold higher 
than the efficacy of the oral insulin administration (4.68 1.52%). These findings suggest 
that these microspheres are promising carrier for oral insulin delivery system. [100] 
15. Jakir Ahmed Chowdhury et al., (2011), developed and Evaluated Diclofenac Sodium 
Loaded Alginate Cross-Linking Beads - Sustained-release polymeric beads containing 
Diclofenac sodium fabricated with sodium alginate were prepared by the ionotropic 
gelation method. Drugs were blended with sodium alginate in 1:1, 1:2, 1:2.5, 1:3, 1:3.5 
and 2:2 ratios. Here, calcium chloride and aluminium sulphate was used as a cross-linking 
agent. Beads of Diclofenac sodium were prepared with different concentrations of drug, 
polymers and electrolytes. Prepared beads were evaluated for their drug entrapment 
efficiency, loss on drying, swelling index and release behavior. The entrapment efficiency 
of drug in beads depended on the amount of drug and polymer ratio as well as electrolyte 
concentration. The percent entrapment was highest when beads were prepared with 5 % 
electrolyte solution. In case of calcium chloride solution with highest amount of polymer 
i.e.3.5 gram the entrapment efficiency was75.12 %. But, in aluminium sulphate solution 
the entrapment efficiency was highest (99.06 %) when polymer amount was 2 gram. In 
most cases, the swelling study revealed that, up to third hour the formulations swelled 
high, but swelling started to decrease after fourth hour. In case of loss on drying of beads 
after formation showed that, the rate of solvent loss until three hours eventually continued 
to increasing but then decreased. In vitro dissolution data showed that, with increasing 
drug, polymer and electrolyte amount the Diclofenac release percentage also decreased. 
Among the sixteen formulations, nine of them followed Higuchi release kinetics. Thus, 
by modifying the polymer amount and the selection of cross linking agent plays a vital 
role in efficiency and sustained-release characteristics. [101] 
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16. Namratapatel et al., (2015), designed and Developed In Vitro Characterization of 
Capecitabine-Loaded Alginate–Pectinate–Chitosan Beads for Colon Targeting. Colon-
targeted capecitabine beads were formulated by an ionotropic gelation method. The 
sodium alginate to pectin ratio and chitosan concentration was optimized using a 32 full 
factorial design. Analysis of response surface plots allowed the identification of an 
optimized formulation with high drug entrapment and controlled release. Insignificant 
differences in observed and predicted values for responses validated the optimization 
method. Optimized beads possessed an average diameter of 1395 µm and good flow 
properties. Their production as spherical beads having a smooth surface was confirmed 
by scanning electron microscopy. Fourier transform infrared spectroscopy revealed the 
compatibility of drug with added excipients, while differential scanning calorimetry study 
confirmed complete drug entrapment in polymer matrix. Higher swelling of beads in 
phosphate buffer pH 7.4 was obtained in comparison to pH 6.8. An in vitro wash off test 
indicated 70% mucoadhesion by the beads. In vitro dissolution studies of beads loaded 
into enteric-coated capsules revealed negligible release in simulated gastric and intestinal 
fluid, followed by 49.23% release in simulated colonic fluid, in 4 h. The optimized beads 
were found to be stable for three months at 25 ± 2°C/60 ± 5% RH. In conclusion, the 
formulated beads showed colon-specific controlled release properties, and thus could 
prove to be effective for colon cancer treatment.[102]  
17. EhsanTaghizadehDavoudi et al., (2013), Prepared and Characterized Gastric Floating 
Dosage Form of Capecitabine Gastrointestinal disturbances, such as nausea and vomiting, 
are considered amongst the main adverse effects associated with oral anticancer drugs due 
to their fast release in the gastrointestinal tract (GIT). Sustained release formulations with 
proper release profiles can overcome some side effects of conventional formulations. The 
current study was designed to prepare sustained release tablets of Capecitabine, which is 
approved by the Food and Drug Administration (FDA) for the treatment of advanced 
breast cancer, using hydroxypropyl methylcellulose (HPMC), carbomer 934P, sodium 
alginate, and sodium bicarbonate. Tablets were prepared using the wet granulation 
method and characterized such that floating lag time, total floating time, hardness, 
friability, drug content, weight uniformity, and in vitro drug release were investigated. 
The sustained release tablets showed good hardness and passed the friability test. The 
tablets floating lag time was determined to be 30–200 seconds, and it floated more than 
24 hours and released the drug for 24 hours. Then, the stability test was done and 
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compared with the initial samples. In conclusion, by adjusting the right ratios of the 
excipients including release-retarding gel-forming polymers like HPMC K4M, Na 
alginate, carbomer934P, and sodium bicarbonate, sustained release Capecitabine floating 
tablet was formulated. [103] 
18. Sanchita Mandal et al., (2010), The objective of this study was to develop a sustained 
release dosage form of Trimetazidine dihydrochloride (TMZ) using a natural polymeric 
carrier prepared in a completely aqueous environment. TMZ was entrapped in calcium 
alginate beads prepared with sodium alginate by the ionotropic gelation method using 
calcium chloride as a crosslinking agent. The drug was incorporated either into preformed 
calcium alginate gel beads (sequential method) or incorporated simultaneously during the 
gelation stage (simultaneous method). The beads were evaluated for particle size and 
surface morphology using optical microscopy and SEM, respectively. Beads produced by 
the sequential method had higher drug entrapment. Drug entrapment in the sequential 
method was higher with increased CaCl2 and polymer concentration but lower with 
increased drug concentration. In the simultaneous method, drug entrapment was higher 
when polymer and drug concentration were increased and also rose to a certain extent 
with increase in CaCl2 concentration, where further increase resulted in lower drug 
loading. FTIR studies revealed that there is no interaction between drug and CaCl2. XRD 
studies showed that the crystalline drug changed to an amorphous state after formulation. 
Release characteristics of the TM loaded calcium alginate beads were studied in enzyme-
free simulated gastric and intestinal fluid. [104] 
19. M Nagpal et al., (2012), The present study was designed to investigate the effects of 
different variables on the release profile of ibuprofen microspheres formulated using 
modified emulsification method. Eight batches of microspheres (F1-F8) were prepared by 
applying 23 factorial design. The amount of sodium alginate, amount of calcium chloride, 
and amount of magnesium stearate were selected as formulation variables. All the batches 
were evaluated in terms of percentage yield, percentage encapsulation efficiency and in 
vitro release characteristics. The batch F7 was found to be optimum batch and was further 
characterized via scanning electron microscopy (SEM) and particle size analysis. 
Multiple linear regression was applied to confirm significant effect of each variable on 
release characteristics. The model developed in the present study can be effectively 
utilized to achieve the formulation with desired release characteristics.[105] 
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20. Sevgi Takka et al., (2010), Bovine serum albumin-loaded beads were prepared by 
ionotropic gelation of alginate with calcium chloride and chitosan. The effect of sodium 
alginate concentration and chitosan concentration on the particle size and loading efficacy 
was studied. The diameter of the beads formed is dependent on the size of the needle 
used. The optimum condition for preparation alginate–chitosan beads was alginate 
concentration of 3% and chitosan concentration of 0.25% at pH 5. The resulting bead 
formulation had a loading efficacy of 98.5% and average size of 1,501 μm, and scanning 
electron microscopy images showed spherical and smooth particles. Chitosan 
concentration significantly influenced particle size and encapsulation efficiency of 
chitosan–alginate beads (p < 0.05). Decreasing the alginate concentration resulted in an 
increased release of albumin in acidic media. The rapid dissolution of chitosan–alginate 
matrices in the higher pH resulted in burst release of protein drug.[106] 
21. VM. Sherina et al., (2012), The objective of the current investigation is to reduce dosing 
frequency and improve patient compliance by designing and systematically evaluating 
sustained release micro beads of Nifedipine. Frequent administration and variable low 
bioavailability (40-50%) after oral administration are problems of conventional dosage 
forms of Nifedipine can be attenuated by designing it in the form of mucoadhesive micro 
beads which would prolong the residence time at the absorption site to facilitate intimate 
contact with the absorption surface and thereby improve and enhance the bioavailability. 
Nifedipine-loaded mucoadhesive micro beads were successfully prepared by ionotropic 
gelation and cross linking technique by using sodium alginate as the hydrophilic carrier in 
combination with HPMC and chitosan polymers as drug release modifiers. Prepared 
beads were evaluated for particle size, swelling ratio, drying rate, drug entrapment, bio 
adhesion study, inviter release, release kinetic and stability study. Particle size 
distribution of both placebo and drug loaded formulations were measured by an optical 
microscope and particle size of optimized beads was determined by SEM. No significant 
drug-polymer interactions were observed in FT-IR studies. In-vitro drug release profile of 
Nifedipine micro beads was examined in phosphate buffer pH 6.8 and exhibited zero 
order kinetic followed by super case II-transport. The in vitro wash-off test indicated that 
the sodium alginate micro beads had good mucoadhesive properties. The drug loaded 
batches were found to be stable when stored at room temperature for 45 days. Hence the 
formulated HPMC coated Sodium alginate beads can be used as an alternative and 
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cheaper carrier for the oral controlled delivery of Nifedipine, especially for the treatment 
of angina pectoris and hypertension. [107] 
22. Nokhodchi A et al., (2004), Small matrices of calcium alginate or aluminium alginate 
have been investigated as possible controlled release systems for drugs. The objective of 
the present study was to sustain the release of theophylline from alginate matrices using 
different concentrations of aluminum chloride and calcium chloride in presence and 
absence of HPMC. Tablets containing differing concentrations of aluminum and calcium 
chloride were produced and the release rate of theophylline was tested using the basket 
dissolution apparatus over 8 h. Increasing amounts of aluminum chloride from 0.0001 to 
0.00068 moles decreased the release of theophylline from 95.1 +/- 0.27 to 29.5 +/- 1.5, 
indicating a significant effect of aluminum ions on a reduction in the release rate of 
theophylline from sodium alginate matrices. In the case of matrices containing different 
concentrations of calcium ions, as the concentration of calcium chloride increased, the 
release rate increased to an optimum then declined after this. This was due to insufficient 
calcium ions being available to cross-link with the sodium alginate to form an insoluble 
gel. The effect of aluminum ions, as this is a trivalent ion compared to calcium, which is a 
divalent ion, aluminum ions are able to decrease the release rate with a smaller 
concentration compared to calcium ions. The results also showed that the presence of 
HPMC caused a reduction in release rate of theophylline from alginate matrices 
containing calcium chloride. Whereas, in the case of alginate matrices containing 
aluminum chloride the release rate of theophylline increased in presence of HPMC. For 
comparing the dissolution data, dissolution efficiency (DE) was used. The values of DE 
are consistent with the dissolution data. The results show that within a formulation series, 
DE values generally decrease when the cation concentration increases and this criterion 
can be used to describe the effect of calcium and aluminum ions on the release behavior 
of theophylline from polymeric matrices. [108] 
23. Phani Kumar G.K et al., (2011), was Isolated and Evaluated of Tamarind Seed 
Polysaccharide being used as a Polymer in Pharmaceutical Dosage Forms. Tamarind seed 
polysaccharide (TSP) obtained from the seed kernel of Tamarindus indica, possesses 
properties like high viscosity mucilage, broad pH tolerance, no carcinogenicity, 
mucoadhesive nature, and biocompatibility. It is used as stabilizer, thickener, gelling 
agent, and binder in food and pharmaceutical industries. The objective of present 
investigation was to search for a cheap and effective natural excipient that can be used as 
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an effective alternative for the formulation of pharmaceutical formulations. Thus this 
mucilage will be a non-toxic, bio-degradable, cheap, economic and easily available option 
as a natural polymer.[109] 
24. Akbuğa J et al., (2013), 5-Fluorouracil-loaded chitosan microspheres: preparation and 
release characteristics Cross-linked chitosan microspheres containing 5-Fluorouracil (5-
FU) were prepared. Variables believed to be important for microsphere properties were 
examined; these included: drug and chitosan concentrations, cross-linking process, the 
type of oil, stirring rate and also additives. Initial 5-FU concentration, the type and 
concentration of chitosan, the viscosity of oil phase and glutaraldehyde concentration 
affected drug release from chitosan microspheres. 5-FU release from cross-linked 
chitosan microspheres is characterized by an initial rapid release of drug. Addition of 
substances such as alginic acid, chitin, agar, sodium caprylate and stearic acid changed 
the release properties of 5-FU microspheres. [110] 
25. Ziyaur Rahman et al., (2006) Characterization of 5-fluorouracil microspheres for 
colonic delivery. The purpose of this investigation was to prepare and evaluate the colon-
specific microspheres of 5-fluorouracil for the treatment of colon cancer. Core 
microspheres of alginate were prepared by the modified emulsification method in liquid 
paraffin and by cross-linking with calcium chloride. The core microspheres were coated 
with Eudragit S-100 by the solvent evaporation technique to prevent drug release in the 
stomach and small intestine. The microspheres were characterized by shape, size, surface 
morphology, size distribution, incorporation efficiency, and in vitro drug release studies. 
The outer surfaces of the core and coated microspheres, which were spherical in shape, 
were rough and smooth, respectively. The size of the core microspheres ranged from 22 
to 55 μm, and the size of the coated microspheres ranged from 103 to 185 μm. The core 
microspheres sustained the drug release for 10 hours. The release studies of coated 
microspheres were performed in a pH progression medium mimicking the conditions of 
the gastrointestinal tract. Release was sustained for up to 20 hours in formulations with 
core microspheres to a Eudragit S-100 coat ratio of 1∶7, and there were no changes in the 
size, shape, drug content, differential scanning calorimetry thermo gram, and in vitro drug 
release after storage at 40°C/75% relative humidity for 6 months. [111] 
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26. Arica B et al., (2002), 5-Fluorouracil encapsulated alginate beads for the treatment of 
breast cancer. Alginate beads containing 5-fluorouracil (5-FU) were prepared by the 
gelation of alginate with calcium cations. Alginate beads loaded with 5-FU were prepared 
at 1.0 and 2.0% (w/v) polymers. The effect of polymer concentration and the drug loading 
(1.0, 5.0 and 10%) on the release profile of 5-FU was investigated. As the drug load 
increased, larger beads were obtained in which the resultant beads contained higher 5-FU 
content. The encapsulation efficiencies obtained for 5-FU loads of 1.0, 5.0 and 10% (w/v) 
were 3.5, 7.4 and 10%, respectively. Scanning electron microscopy (SEM) and particle 
size analysis revealed differences between the formulations as to their appearance and 
size distribution. The amount of 5-FU released from the alginate beads increased with 
decreasing alginate concentrations. [112] 
27. Merve Olukman et al., (2012), Release of Anticancer Drug 5-Fluorouracil from 
Different Ionically cross-linked Alginate Beads. In this research, the release of 5-
Fluorouracil (5-FU) from different ionically cross-linked alginate (Alg) beads was 
investigated by using Fe3+, Al3+, Zn2+ and Ca2+ ions as cross linking agent. The prepared 
beads were characterized by Fourier Transform Infrared Spectroscopy (FTIR) Differential 
Scanning Calorimetry (DSC) and Scanning Electron Microscopy (SEM). The drug 
release studies were carried out at three pH values 1.2, 6.8 and 7.4 respectively each for 
two hours. The effects of the preparation conditions as cross linker type, drug/polymer 
(w/w) ratio, cross linker concentration and time of exposure to cross-linked on the release 
of 5-FU were investigated for 6 hours at 37˚C. It was observed that 5-FU release from the 
beads followed the order of Fe > Zn > Al > Ca-Alg and increased with increasing 
drug/polymer ratio. At the end of 6 hours, the highest 5-FU release was found to be 90% 
(w/w) for Fe-Alg beads at the drug/polymer ratio of 1/8 (w/w), cross linker concentration 
of 0.05 M, exposure time of 10 minutes respectively. The swelling measurements of the 
beads supported the release results. Release kinetics was described by Fickian and non-
Fickian approaches. [113] 
28. Verma Navneet et al., (2016), formulated and evaluated chitosan containing 
mucoadhesive buccal patches of metoprolol succinate; Mucoadhesive buccal patches 
containing metoprolol succinate were prepared using the solvent casting method. 
Chitosan was used as bioadhesive polymer and different ratios of chitosan to PVP K-30 
were used. The patches were evaluated for their physical characteristics like mass 
variation, drug content uniformity, folding endurance, ex vivo mucoadhesion strength, ex 
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vivo mucoadhesion time, surface pH, in vitro drug release, and in vitro buccal permeation 
study. Patches exhibited controlled release for a period of 8 h. The mechanism of drug 
release was found to be non-Fickian diffusion and followed the first-order kinetics. 
Incorporation of PVP K-30 generally enhanced the release rate. Swelling index was 
proportional to the concentration of PVP K-30. Optimized patches (F4) showed 
satisfactory bioadhesive strength of 9.6 ± 2.0 g, and ex vivo mucoadhesion time of 272 
minutes. The surface pH of all patches was between 5.5 and 6.8 and hence patches should 
not cause irritation in the buccal cavity. Patches containing 10 mg of drug had higher 
bioadhesive strength with sustained drug release as compared to patches containing 20 
mg of drug. Good correlation was observed between the in vitro drug release and in vitro 
drug permeation with a correlation coefficient of 0.9364. Stability study of optimized 
patches was done in human saliva and it was found that both drug and buccal patches 
were stable. [114] 
29. Meulenaar J et al., (2014), developed an extended-release formulation of capecitabine 
making use of in vitro-in vivo correlation modeling. An oral extended-release (ER) 
formulation of capecitabine was developed for twice daily dosing, theoretically providing 
a continuous exposure to capecitabine, thus avoiding the undesirable in-between dosing 
gap inherent to the dosing schedule of the marketed capecitabine immediate-release 
formulation (Xeloda(®)). The target 12-hour in vivo release profile was correlated to an 
in vitro dissolution profile using an in vitro-in vivo correlation model based on the 
pharmacokinetic (PK) and dissolution characteristics of Xeloda(®). Making use of the 
slow dissolution characteristics of amorphous capecitabine as reported previously and 
screening of a panel of ER excipients, an ER formulation was designed. Kollidon(®) SR 
induced the most prominent ER. Moreover, it was shown that tablets prepared from 
CoSD capecitabine and Kollidon(®) SR have an additional threefold delay in dissolution 
compared with tablets prepared from the same but only physically mixed components. 
Therefore, a prototype tablet formulation composed of co-spray-dried capecitabine and 
Kollidon(®) SR (98/2%, w/w) mixed with colloidal silicon dioxide (0.5%, w/w) and 
magnesium stearate (2.5%, w/w) was defined. This prototype shows similar dissolution 
characteristics as the modelled dissolution profile. Currently, the in vivo PK of our 
designed ER capecitabine formulations is investigated in a clinical study. [115] 
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30. G. Pavani et al., (2013), Formulated and Evaluated Of Capecitabine Sustained Release 
Tablets. The objective of the present investigation was to formulate and devaluate 
sustained release of Capecitabine tablets. Capecitabine sustained release tablets were 
developed different polymers HPMC K 100, Carbopol 974 and Xanthan Gum with 
different ratios. Totally 9 formulations were prepared. Sustained release tablets of 
Capecitabine were prepared by wet granulation technique. The prepared granules 
evaluated in terms of their Pre-compression studies like Tapped Density, Bulk Density, 
Angle of repose, Carr‟s Index and Hausner‟s ratio. The tablets were evaluated by Post-
compression studies like hardness, thickness, friability and in vitro studies. The results of 
in vitro drug release studies showed that formulation-2 (API and HPMC and Xantham 
gum) has better drug release (98.44%) for 24hrs. [116] 
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AIM AND OBJECTIVE 
Colorectal cancer is the third most commonly diagnosed malignancy and the fourth 
leading cause of cancer-related deaths in the world.  The global burden of colorectal cancer is 
expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 
2030. Rapid increases in both CRC incidence and mortality are now observed in many 
countries particularly in Europe, Asia and South America. Capecitabine drug has been widely 
used for treating colon cancer but it‟s very short plasma half- life (0.85 hours) leads to its 
rapid elimination from the body necessitating its frequent administration. 
The oral colon targeting system refers to the system, in which the release of orally 
administered therapeutic agents is controlled, until they reach cecum or colon. Hence the 
local action can be exerted into the diseased region devoiding destructing the normal cells of 
upper GIT. This approach facilitates the therapeutic efficacy of the drug by minimizing the 
toxic or adverse effect at the same time. Most of the conventional drug delivery systems 
targeting colon fails, as the therapeutic agent don‟t reach up to the colon in appropriate 
concentration. This effective and safe therapy aspiring colon specific delivery is of almost 
challenging task.     
During past few decades, employing natural polymers for the development of various 
drug delivery systems has been time lighted. Natural polymers have ample of advantages like 
easy availability, cost effectiveness, biodegradability and biocompatibility. Alginates are 
generally regarded as safe (GRAS) by the FDA. Na-Alg is a Na salt of alginic acid, which is 
a co-polymer of ȕ-D-alginic acid, which is a co-polymer of ȕ-D-mannuronic acid (m) and α-
L-gluuronic acid (G) having 1,4-glycosidic linkage between them. Many authors were 
reported that calcium alginate beads have been used for oral control drug delivery system but 
it has a main drawback of pH dependent solubility which could lead to fast dissolution rate 
and rapid drug release in gastro intestinal fluid and it also shows poor entrapment efficiency 
due to its poor viscosity.  
In recent year‟s blended polymeric system are exploited in the region of targeted drug 
delivery systems. Biodegradable polymers obtained from Tamarindus indica L. seeds 
received the consideration of several researches because of its economic and easy 
availability. TSP is composed of chemically highly branched carbohydrate polymer. Its 
backbone consists of D-glucose units joined with (1-4) b-linkages similar to that of cellulose. 
It consists of a main chain of b-D- (1-4)-galactopyranosyl unit with a side chain of single 
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xylopyranosyl unit attached to every second, third and fourth of D glucopyranosyl unit 
through a-D- (1-6) linkage. Earlier report was shown while increasing the ratio of the TSP the 
drug loading was found to be maximum might be due to increase in viscosity of the polymer-
blend solutions and could prevent the drug leakage from the beads. 
The objective of the study was to develop colon specific drug delivery system 
(CDDS) which is capable of protecting the drug en route to the colon i.e. drug release and 
absorption should not occur in the stomach as well as the small intestine but only released 
and absorbed once the system reaches the colon. Cross-linked Chitosan succinate was 
reported as pH dependent polymer which was most suitable polymer for colon specific 
delivery system and protected acid degradation of capecitabine in acidic pH. To our best 
knowledge still no reports were available for the study of chitosan succinate cross-linked CP 
loaded AG-TG beads as a novel colon targeted drug delivery system. 
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a) Organoleptic properties  
b) Incompatibility studies 
c) Calibration curve of Capecitabine 
 
3. TAMARIND GUM 
a) Isolation of Tamarind gum 
b) Characterization of Tamarind gum 
 
4. CHITOSAN SUCCINATE 
a) Preparation of Chitosan succinate 
b) Characterization of Chitosan succinate 
 
5. OPTIMIZATION OF BEADS 
a) Preparation of Sodium alginate and Tamarind gum beads 
b) Preparation of Capecitabine loaded Sodium alginate and Tamarind gum beads 
c) Chitosan succinate decorated Capecitabine loaded Sodium alginate and Tamarind 
gum beads 
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DRUG PROFILE 
CAPECITABINE [117-119] 
IUPAC Name:  
Pentyl [1-(3, 4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H 
pyrimidin-4-yl] carbonate 
Structure: 
 
FIG NO: 7 STRUCTURE OF CAPECITABINE 
Molecular Formula : C15H22FN3O6 
Molecular weight : 359.35 
Melting point  : 110-121˚C 
LogP   : 0.4 
Solubility  : It is soluble in water (2ymg/ml) 
Category  : Antineoplastic 
T1/2   : Approximately 38-45 minutes 
Dose   : The usual starting dose is 2,500mg/m2/day in two divided 
    doses, 12 hours apart. One cycle includes two weeks of  
    treatment followed by one week without treatment. Cycles can 
    be repeated every three weeks. 
BCS   : Class type III (High solubility, Low permeability) 
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Pharmacokinetics: 
Absorption: 
 Readily absorbed through GI tract (approximately 70%).Time to reach peak plasma 
concentration for Capectabine is approximately 1.5 hours and for 5-fluorouracil is 2 hours. 
Food decreased peak plasma concentration is 60% and area under curve is 35% for 
Capecitabine and decreased peak plasma concentration (Cmax) 4.3% and area under curve 
21% for 5-fluorouracil. Food delayed Tmax is 1.5 hours. 
Protein binding:  
 Less than 60% protein binding (mainly albumin). 
Metabolism: 
 Metabolized by thymidine phosphorylase to fluorouracil . 
Elimination: 
 Capecitabine and its metabolites are predominantly excreted in urine. About 95.5% of 
administered Capecitabine dose is recovered in urine. Focal excretion is minimal (2.6%). The 
major metabolite excreted in urine is FBAL which represents 57% of the administered dose. 
About 3% of the administered dose is excreted in urine as unchanged drug. 
Mechanism of Action: 
 Capecitabine is a prodrug that is selectively tumor-activated to its cytotoxic moiety, 
fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many 
tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two 
active metabolites, 5-fluoro-2‟-deoxyuridine 5‟-monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP), within normal and tumor cells. These metabolites cause 
cell injury by two different mechanisms. First FDUMP and the folate cofactor, N5-10-
methylenetetrahydrofolate, bind to thymidylate synthase (TS)to form a covalently bound 
ternary complex. This binding inhabits the formation of thymidylate from 2‟-deaxyuridylate. 
Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the 
synthesis of DNA, therefore a deficiency of this compound can inhabit cell division. 
Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of 
uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere 
with RNA processing and protein synthesis through the production of fraudulent RNA. 
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Indications and usage: 
Capecitabine is a nucleoside metabolic inhibitor with anti-neoplastic activity. It is used in the 
treatment of adjuvant colon cancer Stage III Duke‟s C-used as first-line monotherapy. 
Metastatic colon rectal cancer  
First line as monotherapyalone is preferred. 
Metastatics breast cancer  
Asmonotherapy, if the patient has failed paclitaxel based treatment, and if anthracycline 
based treatment, and if anthracycline based treatment has either failed or cannot be continued 
the other reasons. 
Used in combination with docetaxel, after failure of anthracycline based treatment. 
Adverse reactions: 
Most common adverse reactions are: 
Cardiovascular :  EKG changes, myocardial infarction, angina. 
Dermatological  :  Hand and foot syndrome. 
Gastrointestinal :  Diarrhea, Nausea, Stomatitis. 
Heamatological :  Neutropenia, anemia and thrombocytopenia. 
Hepatic  :  Hyperbilirubinemia. 
Drug interaction: 
Anticolagulants :  May interact with warfarin and increase bleeding risk. 
Phenytoin   :  May inhibit cytochrome CYP2C9 enzyme, and therefore  
    increaselevels of substrates such as Phenytoin and other  
    substrates of CYP2C9 
Leucovorin  :  The concomitant use of Leucovorin increased the toxicity of
    Capecitabine without any apparent advantage in response rate. 
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Pharmacodynamics: 
Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the 
treatment of metastatic breast cancer and colon cancer. It is an orally administered systemic 
prodrug that has little pharmacologic activity until it is converted to fluorouracil by enzymes 
that are expressed in higher concentrations in many tumors. Fluorouracil it then metabolized 
both normal and tumor cells to 5-fluoro-2‟-deoxyuridine 5-„monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
POLYMER PROFILE 
SODIUM ALGINATE [120] 
Non-proprietary Names :  BP  : Sodium Alginate        
     PhEur  : Sodium Alginate       
     USP-NF : Sodium Alginate   
Synonym   :  Alginatosodico, Algin, Alginic acid, Sodium salt, E40,
     Kelcosol, Keltone, Natriialginas, Protanal,Sodium  
     polymannuronate. 
Chemical Name  :  Sodium alginate   
Functional category  :  Stabilizing agent, suspending agent, tablet and capsule 
     disintegrate, tablet binder, viscosity increasing agent 
Structural Formula  : 
 
FIG NO: 8 STRUCTURE OF SODIUM ALGINATE 
 
Molecular Weight  : 216.121gm/mol. 
Description   :  Sodium alginate occurs as an odorless and tasteless, 
     white to pale yellowish-brown colored powder.   
 
 
 
64 
Solubility:   
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water mixtures in 
which the ethanol content is greater than 30%. Also, practically  insoluble in other organic 
solvents and aqueous acidic  solutions in which the pH is less than slowly soluble in water, 
forming a viscous colloidal solution.    
Viscosity:  
Typically, a 1% w/v aqueous solution, at 20ºC, will have a viscosity of 20– 400 mPas (20–
400 cP). Viscosity may vary depending upon concentration, pH, temperature, or the presence 
of metal ions. Above pH 10, viscosity decreases.   
Incompatibilities:  
Sodium alginate is incompatible with acridine derivatives, crystal violet, phenyl mercuric 
acetate and nitrate, calcium salts, heavy metals, and ethanol in concentrations greater than 
5%. Low concentrations of electrolytes cause an increase in viscosity but high electrolyte 
concentrations cause salting-out of sodium alginate; salting-out occurs if more than 4% of 
sodium chloride is present.   
Stability and storage condition:  
Stable, the bulk material should be stored in an airtight container in a cool, dry place.   
Safety:  
It is generally regarded as a nontoxic and nonirritant material, although excessive oral 
consumption may be harmful.   
Application in pharmaceutical formulation or technology:  
Sodium alginate is used in a variety of oral and topical pharmaceutical formulations. In tablet 
formulations, sodium alginate may be used as both a binder and disintegrate, it has been used 
as a diluent in capsule formulations. Sodium alginate has also been used in the preparation of 
sustained-release oral formulations. In topical formulations, sodium alginate is widely used as 
a thickening and suspending agent in a variety of pastes, creams, and gels, and as a stabilizing 
agent for oil-in-water emulsions. Recently, sodium alginate has been used for the aqueous 
microencapsulation of drugs.   
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ZINC SULPHATE [120] 
 
Description  : Zinc sulphate is the inorganic compound with the 
  formula ZnSO4 as well as any of three hydrates. It was 
  historically known as "white vitriol". All of the various 
  forms are colorless solids. The heptahydrate is  
  commonly encountered. It is on the World Health  
  Organization's List of Essential Medicines, a list of the 
  most important medication needed in a basic health  
  system. 
Structure   : 
 
FIG NO: 9 STRUCTURE OF ZINC SULPHATE 
Categories  : Acids,  Non-carboxylic acids, Alimentary Tract and 
  Metabolism, Anions, Astringents, Dermatologic Agents, 
  Electrolytes, Ions, Mineral Supplements, Sulfates,  
  Sulfur Acids, Sulfur Compounds, Sulfuric Acids,  
  Zinc Compounds. 
Chemical Formula  : ZnSO4 
IUPAC Name  : Zinc(2+) ion sulphate 
Indication  : This medication is a mineral used to treat or prevent low 
  levels of zinc. In medicine it is used together with oral 
  rehydration therapy (ORT) and an astringent. Zinc  
  Sulfate Injection, USP is indicated for use as a  
  supplement to intravenous solutions given for TPN. 
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Pharmacodynamics  : Zinc has been identified as a cofactor for over 70  
  different enzymes, including alkaline phosphatase,  
  lactic dehydrogenase and both RNA and DNA  
  polymerase. Zinc facilitates wound healing, helps  
  maintain normal growth rates, normal skin hydration 
  and the senses of taste and smell. 
Mechanism of action : Zinc inhibits cAMP-induced, chloride-dependent fluid
 secretion by inhibiting basolateral potassium (K)  
 channels, in in-vitro studies with rat ileum. This study 
 has also shown the specificity of Zn to cAMP-activated 
 K channels, because zinc did not block the calcium 
 (Ca)-mediated K channels. As this study was not 
 performed in Zn-deficient animals, it provides evidence 
 that Zn is probably effective in the absence of Zn 
 deficiency. Zinc also improves the absorption of water 
 and electrolytes, improves regeneration of the intestinal 
 epithelium, increases the levels of brush border 
 enzymes, and enhances the immune response, allowing 
 for a better clearance of the pathogens. 
Absorption  : Approximately 20 to 30% of dietary zinc is absorbed, 
  primarily from the duodenum and ileum. The amount 
  absorbed is dependent on the bioavailability from food. 
  Zinc is the most bioavailable from red meat and oysters.
  Phytates may impair absorption by chelation and  
  formation of insoluble complexes at an alkaline pH. 
  After absorption, zinc is bound in the intestine to the 
  protein metallothionein. Endogenous zinc can be  
  reabsorbed in the ileum and colon, creating an  
  enter pancreatic circulation of zinc. 
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Volume of distribution : After absorption zinc is bound to protein  
  metallothionein in the intestines. Zinc is widely  
  distributed throughout the body. It is primarily stored in 
  RBCs, WBCs, muscles, bones, Skin, Kidneys, Liver, 
  Pancreas, retina, and prostate. 
Protein binding  : Zinc is 60% bound to albumin; 30 to 40% bound to 
   alpha-2 macroglobulin or transferring; and 1% bound
   to amino acids, primarily histidine and cysteine. 
Route of elimination  : Primarily fecal (approximately 90%); to a lesser extent
  in the urine and in perspiration. 
Half-life   : 3 hours 
Toxicity   : Human:TDL  Oral) 45mg/kg/7D-C : Normocytic  
  anemia, pulse rate increase without fall inBP Human:  
  TDL. (oral) 106mg/kg : Hypermotylity, diarrhea   
  Mouse ; LD50 Oral : 245mg/kg Mouse : LD50 :   
  subcutaneous : 781mg/kg. 
Substituents   : Transition metal sulphate, Inorganic oxide, Inorganic 
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CHITOSAN SUCCINATE [120] 
Structure   : 
 
FIG NO: 10 STRUCTURE OF CHITOSAN SUCCINATE 
Chitosan succinate Synthesis: Synthesis of chitosan succinate: DAC (1.0g) was  
     dissolved in dimethyl sulfoxide (20ml). Prescribed  
     succinc anhydride (1.0g) was added to the diluted  
     solution and stirred at 60 C. After standing for 24h, the 
     pH of the mixture was adjusted to with 5% w/v aq. 
     NaOH to give a precipitate. The precipitate was  
     collection by filtration and dispersed in 50ml of H2O. 
     the pH of the dispersion was adjusted to 10-12 with w/v 
     aq. NaOH to give a pale yellow solution.. The solution 
     was dialysed using dialysis membrane (molecular  
     weight of, 12000-14000) at room temperature for 2-3 
     days and lyophilized. The lyophilized samples were 
     recovered. The synthesis route was shown in fig 11. 
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FIG NO: 11 SYNTHESIS OF CHITOSAN SUCCINATE 
Isoelectric point  : Chitosan succinates has both amino and carboxy group. 
     The isoelectric point which exists equimolar of NH3* 
     and -COOH‟ are calculated and was found to be 526. 
Solubility   : Solubility of chitosan succinate was studied in water of 
    various pH. It showed good solubility in the basic  
    region above pH 7.8 and this is may be due to  
    protonation of amino group. 
Those with a family history I two or more first degree relatives have a two to 
threefold greater risk of disease and this group accounts for about 20% of a; cases. A number 
of genetic syndromes are also associated with higher rates of colorectal cancer. 
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List of materials and suppliers 
Table 2: List of materials used 
S.NO RAW MATERIALS MANFACTURER 
1. Capecitabine Sigma aldrich private limited 
2. Chitosan Mahtani private limited 
3. Pyridine Rolex laboratory reagent 
4. Ethyl alcohol Merck life science private limited 
5. Sodium alginate S.D Fine Chemicals, Mumbai India 
6. Zinc Sulphate S.D Fine Chemicals, Mumbai India 
7. Glutraldehyde Lobachemie laboratory and fine chemicals 
8. Ethanol Lobachemie laboratory and fine chemicals 
 
List of equipment‟s and manufacturer  
Table 3: List of instruments used 
S.NO INSTRUMENTS MANFACTURER 
1. Electronic balance Wensar 
2. Digital pH meter Elico 
3. Sonicator Vibro cell 
4. Dissolution apparatus Electrolab 
5. Magnetic stirrer Remi motors 
6. Mechanical shaker Technical lab 
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7. UV spectrometer Shimadzu, Japan 
8. Fourier transit infra-red 
spectroscopy 
Thermo scientific Nicolet ISF 
9. Scanning electron microscopy JEOL 
10. Electronic microscope LW electronic microscopes 
11. Hot air oven Techno lab 
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CHARACTERIZATION OF DRUG [115] 
Organoleptic properties:  
The organoleptic characters of the drug like colour, odour, taste and appearance play 
an important role in the identification of the sample and hence they should be recorded in 
descriptive terminology.  
Solubility studies:  
An excess of drug is suspended in 100ml of dissolution medium containing various 
concentrations of carriers in stopper flask and equilibrated by intermittent shaking for 72 hrs 
maintained at 37±20c.The solution is filtered through whattman filter paper. A portion of 
filtrate is diluted suitably and analyzed by UV spectroscopy. 
ESTIMATION OF CAPECTABINE 
STANDARD GRAPH OF CAPECITABINE [116] 
CONSTRUCTION OF STANDARD GRAPH OF CAPECITABINE (0.1 N HCL) 
PREPARATION OF STOCK SOLUTION 
Accurately weighed amount of 100 mg was transferred into a 100ml volumetric flask. 
Few ml of water was added to dissolve the drug and volume was made up to 100 ml with 0.1 
N HCl. The resulted solution had the concentration of 1mg/ml which was labeled as “stock”. 
PREPARATION OF WORKING STANDARD SOLUTION 
From this stock solution 10ml was taken and diluted to 100 ml with 0.1 N HCl which 
has given the solution having the concentration of 100mcg/ml. 
PREPARATION OF SERIAL DILUTIONS FOR STANDARD CALIBRATION CURVE 
Necessary dilutions were made by using the standard solution to give the different 
concentrations of Capecitabine (0-60mcg/ml) solutions. The absorbance of above solutions 
were recorded at max (303nm) of the drug using double beam UV-Visible 
spectrophotometer. Standard graph was plotted between the concentration (on X-axis) and 
absorbance (on Y-axis). 
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CONSTRUCTION OF STANDARD GRAPH OF CAPECITABINE (PH5.8 BUFFER) 
PREPARATION OF STOCK SOLUTION 
Accurately weighed amount of 100 mg was transferred into a 100ml volumetric flask. 
Few ml of water was added to dissolve the drug and volume was made up to 100 ml with pH 
5.8 buffer. The resulted solution had the concentration of 1mg/ml which was labeled as 
“stock”. 
PREPARATION OF WORKING STANDARD SOLUTION 
From this stock solution 10ml was taken and diluted to 100 ml with pH 5.8 buffer 
which has given the solution having the concentration of 100mcg/ml. 
PREPARATION OF SERIAL DILUTIONS FOR STANDARD CALIBRATION CURVE 
Necessary dilutions were made by using this second solution to give the different 
concentrations of capecitabine (0-20mcg/ml) solutions. Theabsorbance of above solutions 
was recorded at max (303nm) of the drug using double beam UV-Visible spectrophotometer. 
Standard graph was plotted between the concentration (on X-axis) and absorbance (on Y-
axis). 
 
CALIBRATION CURVE OF CAPECITABINE (pH 7.4) 
An accurately weighed quantity of 100mg Capecitabine was transferred into a 100ml 
standard flask and volume was made up to the mark using Phosphate buffer of pH 7.4. From 
the primary stock solution 2ml was transferred to 100 ml volumetric flask and diluted upto 
the mark using Phosphate buffer of pH 7.4. The concentration of the solution will be 
20μg/ml. Various concentrations 4μg, 8μg, 12μg, 16μg, 20μg, 24μg, 28μg 32μg, were 
prepared by diluting 1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 9ml and 10ml of the stock 
solution to 10ml using buffer of pH 7.4 respectively. The absorbance was noted at 303nm 
using UV/Vis Spectrophotometer.  
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EXTRACTION PROCEDURE 
Tamarind seeds were purchased from the seeds shop situated in the chennai, India. 
Seeds were boiled and mucilage was taken out. Mucilage was dried, powdered and further 
passed from sieve # 20 and stored in air tight container until used.  
Extraction of tamarind polysaccharide includes two steps:  
Step 1: Extraction of tamarind polysaccharide  
Tamarind gum extracted by tamarind seeds were done as following  
Crude tamarind seeds were washed neat and clean then kept for 3 hrs boiling. After 
completion of boiling, boiled seeds were kept for cooling for 24 hrs so that mucilage is being 
expelled out from the seeds. Completing 24 hrs of expulsion of mucilage from seeds, heat 
them for few minutes then set for cooling. Pour seeds with mucilage in the muslin cloth and 
press till all the mucilage is squeezed from the seeds. Temperature of extraction media was 
maintained at 70˚C and duration of extraction was adjusted about 6 hrs.[121,122] 
Step 2: Isolation of tamarind seed polysaccharide  
In hot water boiled tamarind seeds were kept for 24 hrs so that the mucilage can come 
out from the seeds. After 24 hrs, boiled the seeds containing tamarind gum for 1 hr. Water 
extracted juice were squeezed with muslin cloth bag and the concentrated juice was cooled to 
4˚C. Tamarind seed polysaccharide tamarind gum was precipitated by alcohol-juice treatment 
2:1(v/v) followed by continuous stirring for 15 min and mixture was further allowed to stand 
for 2 hrs for better tamarind seed polysaccharide precipitation. This allows filtering of 
polysaccharide substances because tamarind seed polysaccharide remains float on the surface 
of alcohol-water mixture. Floating tamarind polysaccharide coagulate was filtered through 
muslin cloth, washed with alcohol (95%) and squeezed. Squeezed tamarind seed 
polysaccharide was further dried to constant weight at 35-45°C in hot air oven. Hard 
tamarind seed polysaccharide cake was ground and sieved through sieve # 20, stored in 
desiccators for further use. 
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PHYSICOCHEMICAL CHARACTERIZATION OF TAMARIND SEED 
pH of Tamarind Seed Polysaccharide:  
Firstly, extracted tamarind gum was weighed and then dissolved in water separately to 
get a 1% w/v solution. The pH of solution was determined using pH meter.[123] 
Powder properties  
The flow properties of the sample were investigated by the angle of repose, bulk 
density and tapped density measurements. The angle of repose was determined on 50 g of 
sample using Borosilicate glass funnel (with orifice diameter and a base diameter of 6.5 mm 
and 8 cm respectively). Bulk and tapped densities were measured in 100 ml of graduated 
cylinder. The sample contained in the cylinder was tapped mechanically by means of Auto-
Tap Shaker .The tapped volume was noted down when it showed no change in its value. The 
data generated from bulk densities and tapped densities were used in figured the Carr‟s index 
and Hausner‟s ratio for the tamarind seed powder. True density was obtained by helium 
pycnometer. The data generated from bulk density and true densities were utilized for 
calculating the porosity of powder mass. Moisture content was determined by official method 
of USP32-NF27 in a mechanical convection oven at 105˚ C to the weight constants. 
Solubility behavior  
One part of dry tamarind seed polysaccharide powder was shaken with different 
solvents and their solubility was determined. Solubility of tamarind seed polysaccharide was 
determined in basic solvents i.e Acetone, Chloroform, Hexane, Butanol and Water. It has 
been observed that polysaccharide is soluble in every solvent.[123] 
SYNTHESIS OF CHITOSAN SUCCINATE 
The reaction was carried out according to the previously reported method. Briefly, 
chitosan (1.00 g, corresponding to approximately 6.20mmols glucosamine) was dissolved in 
HCl aqueous solution (0.37%,50 ml) at ambient temperature, and a solution of the anhydride 
(6.25mmol; succinic 0.63 g) in pyridine (5 ml) was added dropwise withvigorous stirring. 
The reaction pH was maintained at 7.0 by the drop wiseaddition of NaOH solution (1.0 M). 
NaOH addition was continued till thepH was stabilized. After 40 min the reaction was 
terminated by the additionof NaCl aqueous solution (20%, 200 ml). The resulting precipitate 
wasfiltered, washed with acetone and diethyl ether, and desiccated to givechitosan succinate 
conjugates. 
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CHARACTERIZATION OF CHITOSAN SUCCINATE 
Determination of Degrees of Substitution on Chitosan and UV Analysis 
The degrees of phthalate or succinate substitution on chitosan were determined as 
follows: Chitosan conjugates (0.10 g) were completely hydrolyzed in a NaOH aqueous 
solution (3.0 M) and over 48 h. The concentrations ofsuccinic acids in the hydrolysis 
solutions were determined byUV measurement, at l = 228 nm for succinicacid. Non-
conjugated chitosan was treated in the same way, and the resulting solution was used as a 
blank. The degree of substitution (expressed as g %)is defined as the ratio of the measured 
amount of succinic acid(in grams) in the hydrolysis solution, to the amount of the 
hydrolyzedchitosan conjugates (in grams)[114].  
Solubility of polymer 
Chitosan and CS polymer were placed in a 100 ml screw-capped bottle containing 
different pH solution (pH 1.2, 4.5 and 7.4). The polymeric suspension was then shaken using 
amechanical shaker (Techno Lab, Chennai) at room temperature for 48 h. The suspensionwas 
then filtered and left overnight to dry under vacuum. The dissolved amount was then 
calculated by weight difference. 
OPTIMIZATION OF BEADS [100] 
Two optimization processes was carried out to optimize: 1. Preparation of sodium 
alginate tamarind gum beads using ZnSO4as a cross linker 2. Preparation of Chitosan 
succinate coated alginate tamarind beads using Glutraldehyde as a cross linker. 
Optimization of  A three-factor, one response design is suitable for exploring 
quadratic response surfaces and for constructing second order polynomial models with 
Design Expert ® (version10) Stat-Ease Inc., Minneapolis, Minnesota). The independent and 
dependent variables are listed in Table 4 and 5 along with their low, medium and high levels. 
The polynomial equation generated by this experimental design is given as: 
Y0 = b0+b1A+b2B+b3C+b12AB+b13AC+b23BC+b23BC+b11A2+b22B2+b33C2 
Where dependent variable Y1drug release for the both optimization process, and A, B and C 
are the independent variables representing sodium alginate, tamarind gum and calcium 
chloride concentrations for optimization of process one and alginate tamarind gum ratio, 
Chitosan succinate and glutraldehyde concentrations for optimization process two, 
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respectively. b0 is a constant; b1,b2 and b3 are the coefficients translating the linear weight of 
A, B and C, respectively; b12 , b13 and b23 are the coefficients translating the interactions 
between the variables; and b11 , b22 and b33 of the coefficients translating the quadratic 
influence of A, B and C for the both optimizations. Linear and second-order polynomials 
were fitted to the experimental data to obtain the regression equations, and their observed and 
predicted responses are given in Table 13 and 14. 
 
Table: 4Design of experiment-levels of various process parameters 
 
Table: 5 Design of experiment-levels of various process parameters 
 
 
 LEVEL USED 
FACTORS LOW(-1) MEDIUM(0) HIGH(+1) 
A – Sodium alginate concentration 
(%w/v) 
2 4 6 
B– Tamarind gum concentration (%w/v) 2 4 6 
C– Zinc sulphate concentration (%w/v) 10 15 20 
 LEVEL USED 
FACTORS LOW(-1) MEDIUM(0) HIGH(+1) 
A – Sodium alginate and TG ratio (%w/v) 2:6 4:4 6:2 
B– Chitosan succinate concentration 
(%w/v) 
2 4 6 
C– Glutraldehyde concentration (%w/v) 7.5 10 12.5 
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PREPARATION OF CHITOSAN SUCCINATE DECORATED SODIUM 
ALGINATE TAMARIND GUM BEADS 
The concentrations of sodium alginate and zinc sulphate were optimized by 
preliminary experimentation in which blank beads were prepared using varying 
concentrations. The concentrations which yielded spherical beads having sufficient integrity 
were selected for preparing drug loaded beads. The composition of the various batches along 
with the observation is shown in Table 13 and 14. Drug loaded chitosan succinate – sodium 
alginate tamarind gum beads were prepared by ionotropic gelation method. The following 
solutions were made separately: Solution A-Accurately weighed quantities of sodium alginate 
(6%w/v) tamarind gum (4%w/v) andcapecitabine (200mg) were dissolved in 15 ml de-
ionized water by continuous stirring for 30 minutes using a magnetic stirrer. Solution B: 
Accurately weighed quantity of zinc sulphate (10%w/v) was dissolved in 35 ml de-ionized 
water. To this solution, 10ml of solution containing Chitosan succinate (dissolved in 2% 
NaOH) with pH adjusted to 7±1 was added. Solution A was then extruded drop wise into 
solution B through hypodermic syringe with needle (20G) and stirred for 15 minutes at 
50rpm using magnetic stirrer. This led to ionotropic gelation of sodium alginate in the form 
of beads. Stirring was continued for 30 minutes for completion of the gelation. The beads 
were then filtered using a man filter paper and air dried overnight. The prepared bead was 
cross-linked by glutraldehyde. The beads were spread uniformly in a petridish and kept in a 
desiccators containing glutraldehyde at the bottom. The beads were exposed to the 
Glutraldehyde solution for 4 hours. 
CHARACTERIZATION OF CHITOSAN SUCCINATE DECORATED 
SODIUM ALGINATE TAMARIND GUM BEADS 
%Yield 
The prepared beads were weighed using a calibrated weighing balance and the % 
yield was calculated using the following equation:[124] 
% yield= W/T 
Where, W= weight of the beads  
T= Total weight of sodium alginate and capecitabine taken 
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Drug loading and entrapment efficiency [124] 
Accurately weighed beads (10 mg) were transferred to a beaker containing 10 ml 
Phosphate buffer pH 6.8 and the mixture was allowed to stand for 24 hours. The contents of 
the beaker were stirred for 1-2 hours using a magnetic stirrer for complete breakage of the 
beads, followed by filtration using what man filter paper. The amount of capecitabine(x) in 
10 mg beads was then estimated in the filtrate by measuring the absorbance at 303 nm using 
U.V.-visible spectrophotometer. Drug loading and Entrapment efficiency was then calculated 
by following formulae: 
Drug loading (%w/w) = 10x 
% Entrapment efficiency=(x /T)*100 
Where, x = Actual quantity of drug present in beads 
T = Theoretical quantity of drug added during preparation 
Micromeritic properties [124] 
The size of beads was determined using optical microscopy technique. The beads 
were spread uniformly on a glass slide and observed under microscope. The size of 50 beads 
from each batch was determined using a calibrated eye piece micrometer and average was 
calculated. Angle of repose was measured by fixed base cone method. Bulk and tapped 
densities as measures of pack-ability of beads were measured using a 5 ml graduated 
cylinder. 1 gm of sample was added in the cylinder and volume occupied by sample was 
noted and bulk density was calculated. The cylinder was tapped 100 times and volume 
occupied was again measured to calculate tapped density.  
 
Bulk density = (weight of sample / volume occupied by sample before tapping)  
Tapped density= (weight of sample/ sample occupied by sample after tapping) 
Carr‟s index and Hausner‟s ratio were also calculated as measures of powder flow properties 
using the following equations:  
100' X
DensityTapped
yBulkDensitDensityTapped
sIndexCarr 
 
Hausner‟s ratio= (Tapped density / Bulk density) 
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SIZE, SHAPE AND SURFACE MORPHOLOGY [124] 
The beads were analyzed microscopically under digital microscope (Nikon digital 
sight, DS-Fi20) to study their size and shape. The size of the beads was determined by using 
a calibrated eye piece micrometer. The surface morphology of beads was studied using 
scanning electron microscopy (JSM-5610LV, JEOL, Japan). For this, samples were attached 
to sample stubs; silver coating was done and then viewed using an accelerating voltage at the 
magnification of 15000X. 
SWELLING INDEX [124] 
Accurately weighed 50mg of beads were taken in a beaker containing 10 ml of 
phosphate buffer 0.1 N HCL, 5.8 and 7.4 then allowed to stand at room temperature for 6 hr. 
The excess liquid adhered to the surface of the beads was removed by blotting with filter 
paper and the swollen beads were weighed. Each experiment was carried out in triplicate. The 
swelling index of the beads was calculated by using the formula: 
2
21
Wt
WtWt 
 
FTIR Studies[124] 
Drug polymer interactions were studied by FT-IR spectroscopy. One to 2mg 
ofCapecitabine, polymer and physical mixturesofsamples were weighed and mixed properly 
withPotassium bromide to auniform mixture. A small quantity of the powder was compressed 
into athin semitransparent pellet by applying pressure. The IR spectrum of the beads from 
450-4000cm-1 was recorded taking air as the reference and compared to study any 
interference. 
Thermal Analysis[124] 
Differential scanning calorimetry of microspheres was performed with a Pyris 6 DSC 
(Perkin ElmerCorp., Waltham, MA). Samples (5 mg) were scanned in aluminum pans over a 
temperature range between 50 and 400˚C at a scanning rate of 10˚C/min. Nitrogen was used 
for purging the sample holder at a flow rate of 20 Ml/min. Thermogravimetricanalysis (TGA) 
of chitosan succinate beads powder was done on a Mettler Toledo (Greifensee, Switzerland) 
and sample was heated between 25and 250˚C at 10˚C/min. 
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IN-VITRO RELEASE STUDIES [125] 
In-vitro release studies of prepared beads were carried outto900 ml of 0.1 N HCl (pH 
1.2). The test was carried out in 0.1 N HCl for 2 h, and then using phosphate buffer (pH 7.4) 
using USP- XXII apparatus at 100 rpm, maintained at a temperature of 37±10˚C for a period 
up to 12 hrs. Each time interval 5 ml of sample was withdrawn, at the same time 5 ml of fresh 
dissolution media was added to maintain sink condition. The withdrawn samples were 
suitably diluted and measure the absorbance at 247 nm spectrophotometrically. Depend upon 
the absorbance values; we got the concentration values from the standard calibration curve. 
Then the cumulative percentage drug release was calculated at regular time intervals. 
Dissolution Kinetics of Drug Release [125] 
To study the release kinetics, data obtained from in vitro drug release studies were 
plotted in various kinetic models: Zero order (cumulative amount of drug released vs. time), 
First order (log cumulative percentage of drug remaining vs. time), Higuchi‟s model 
(cumulative percentage of drug released vs. square root of time), Hixon-Crowell (cube root of 
amount remained to be absorbed vs. time) and Korsmeyer‟s (log cumulative percentage of 
drug released Vs log time). 
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CHARACTERIZATION OF TAMARIND GUM [121, 122] 
It has been observed that isolated tamarind gum was whitish brown in color. It consist 
of no odor and taste along with irregular shape as well as hard and rough in sensation and 
texture. The pH of 1% solution of TG was found 6.4, which indicated that it should be non-
irritating for mucus membrane. Solubility study showed that it was sparingly soluble in cold 
water, freely soluble and form viscous colloidal solution in warm water. The isolated sample 
of TG was subjected to identification.  
Percentage Yield 
The % yield of the polysaccharide was found to be 70.0% for tamarind. During the 
processing of tamarind gum isolation washing is required many times which may result in 
loss of dissolved polysaccharides. However extraction process of tamarind is easy and hence 
gives better yield. 
Solubility in various solvents  
The solubility was checked in common solvents depending on their polarity such as 
water, phosphate buffers pH7.4, 0.1N HCl, acetone, ethanol, methanol. The polysaccharide 
was found to be soluble in organic solvents and is also soluble in the aqueous solvents and 
swells to make a viscous solution. Hence the polysaccharides are hydrophilic in nature.  
Particle size and size distribution  
The mean particle size of 1%, w/v TG solution was 28.527 μm. 
Powder Properties 
The polysaccharides were subjected to the analysis of powder flow properties such as 
bulk density, tap density, Carr‟s index (CI) and Hausner ratio (HR). Direct compression of 
powders requires when materials show good flow ability, comapactibility and 
compressibility. These constraints become more decisive when the formulation contains large 
amount of active substances with poor compression properties. The % CI range in between 
24-31 stands for poor flow. Again HR ranges in between 1.30-1.45 also possess poor flow. 
From the investigation the values were found to be in this range for all three polysaccharides. 
Hence they are of poor flow properties. The probable reason may be due to the high 
intermolecular force of attraction among the particles. It may be due to inadequate freeze 
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drying of the sample resulting fluffy powder which are tough to be sieved. The results are 
shown in Table 6. 
Rheological Behavior 
The viscosities of the different concentration (0.5%, 0.75% and 1%, w/v) of TG 
solutions were determined by Brookfield viscometer at different shear. All the solutions 
showed sufficient viscosity at different shear rate and shows pseudoplastic flow. This was 
observed that viscosity decreases correspondingly with increasing shear. TG shows consistent 
change behavior upon application of pressure. 
Table: 6 Powder characteristics and flow properties of tamarind gum powder 
Description  Values  
Angle of repose(degree)   27.35±0.12 
Compressibility index(%CI)   4.25±0.150 
Hausner‟s ratio(H)   1.03±0.06 
Bulk density(ρo)   0.63±0.03 
Tapped density(ρ)   0.749±0.016 
Mean particle size (μm)   81.63±42.16 
True density   0.83± 0.04 
% porosity   41.67±2.34 
% moisture content   4.31±0.78 
Ash value (%)   6.23±0.251 
 
SYNTHESIS AND CHARACTERIZATION OF CHITOSAN 
SUCCINATE POLYMER 
Chitosan Succinate (CS) was prepared and yield was found 90%. The conjugation 
reactions were carried out using succinate anhydrides in the presence of pyridine. Both 
anhydrides are strong electrophiles and react readily with the nucleophilic amine groups of 
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chitosan. Pyridine was added as an acylation catalyst. Probably, the amino groups were 
selectively acylated due to their superior nucleophilic character in comparison to the 
surrounding hydroxyl groups. The average degree of chitosan substitution by succinate 
moieties was found to be 12.3%. The solubility of CS was carried out in acidic and alkaline 
solution. In contrast to chitosan, semi-synthetic polymers exhibit the highest solubility in 
alkaline media; this is probably due to ionization of the carboxylic acid moieties under 
alkaline conditions yielding the sodium carboxylate anions. The hydrophilic ionic species 
facilitate efficient polymeric hydration and dissolution in aqueous media. 
CHARACTERIZATION OF THE PURE DRUG 
Standard Graph of Capecitabine in 0.1 N HCl 
The standard graph of capecitabine has shown good linearity with R2 values 0.9991 in 
0.1 N HCl and which suggests that it obeys the “Beer-Lambert‟s law”. 
 
Table No: 7 Standard values of Capecitabine in 0.1N HCL 
 
S.NO 
 
CONCENTRATION 
 
ABSORBANCE 
AT 303nm 
1. 0 0 
2. 10 0.19 
3. 20 0.335 
4. 30 0.50 
5. 40 0.68 
6. 50 0.82 
7. 60 0.998 
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Fig No: 12 Calibration curve of Capecitabine in 0.1N HCl 
STANDARD GRAPH OF CAPECITABINE IN 5.8 pH PHOSPHATE BUFFER  
The standard graph of Capecitabine has shown good linearity with R2 values 0.9947 
and which suggests that it obeys the “Beer-Lambert‟s law”.  
Table No: 8 Standard values of capecitabine in 5.8 pH phosphate buffer 
S.NO CONCENTRATION ABSORBANCE AT 303nm 
1. 0 0 
2. 5 0.178 
3. 10 0.355 
4. 15 0.554 
5. 20 0.704 
6. 25 0.825 
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Fig No: 13 Calibration curve of Capecitabine in 5.8 pH buffer 
 
STANDARD GRAPH OF CAPECITABINE IN 7.4 pH PHOSPHATE BUFFER  
The standard graph of Capecitabine has shown good linearity with R2 values 0.9993 
and which suggests that it obeys the “Beer-Lambert‟s law”.  
Table No: 9 Standard values of capecitabine in 7.4 pH phosphate buffer 
S.NO CONCENTRATION ABSORBANCE AT 303nm 
1. 0 0 
2. 4 0.545 
3. 8 1.051 
4. 12 1.509 
5. 16 2.01 
6. 18 2.254 
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7. 20 2.492 
8. 24 2.962 
9. 28 3.4 
 
 
 
Fig No: 14 Calibration curve of Capecitabine in 7.4 pH buffer 
PHYSICAL PROPERTIES OF CAPECITABINE BLEND 
The pure drug was observed as White to light yellow in colour, odourless, appearance 
as powder in nature.  Melting point of the drug was found to be 116 -117ºC and soluble in 
water, Ethanol, acetonitrile, dimethyl formamide, marginally soluble in methanol. 
OPTIMIZATION OF BEADS [100] 
Response Y1: Effect on in vitro drug release: 
Seventeen formulations were prepared and evaluated for experimental design of three-
factor, one response set-up. The evaluated responses were drug release for the both the 
optimizations. Beads  prepared with low concentration of polymers (- level) were rough and 
irregular in shape due to poor molecular packing and cross-linking in comparison with beads 
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prepared with medium and high concentration of polymers ( +level) which were larger and 
more spherical. The variation in size and morphology of the beads with different polymeric 
concentrations was due to variations in availability of reacting/binding sites for cross-linking 
cations. As the cross-linking agent content was increased, smooth, spherical and smaller 
beads were obtained which were well packed and discrete (Figure – 16 and 20). 
Further, we analyzed the effect of polymer concentration on drug release which was 
more intricate. The drug release was being affected by both of the polymers but in a 
reciprocal mode. Drug release was directly proportional to the amount of polymer 
concentration, while it was inversely proportional to the amount of cross linking agents in 
both the optimizations.  
The mathematical relationship in the form of a polynomial equation for the measured 
response, % of drug release (Y1) released from sodium alginate tamarind gum beads 
(Equation 4) and chitosan succinate decorated glutraldehyde sodium alginate tamarind gum 
(Equation 5), are given below: 
Y1= +65.00+15.37A-0.38B-8.50C+9.75A2+6.25B2-1.00C2+0.000AB+1.25AC-0.25BC  (4) 
Y2= +2.00+0.000A-3.00B-8.25C-0.25A2-4.25B2-7.75C2-0.50AB+0.000AC+3.50 BC   (5) 
where A, B and C represents the sodium alginate, tamarind gum and amount of calcium 
chloride concentrations for optimization 1 and sodium alginate tamarind gum ratio, chitosan 
succinate and amount of glutraldehyde concentrations for optimization 2 respectively. A 
positive value represents an effect that favours the optimization, while a negative value 
indicates an antagonistic effect. The values of A, B, and C were substituted in the equation to 
obtain the theoretical values of Y1. The predicted values and the observed values were found 
to be in good agreement. The effect of pair wise interaction of the parameters is depicted in 
the three dimensional graphs (Figures 15-20) when the third parameter is kept constant. The 
optimum condition for the preparation of chitosan succinate decorated sodium alginate 
tamarind gum capecitabine beads as evident from Table No: 13 and Figure No: 18 . 
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Table: 10 Regression analysis for response Y1 and Y2 
Model R-squared Adjusted 
R-squared 
Predicted 
R-squared 
SD Remarks 
Response (Y1) 
 Linear 
 Second order 
 Quadratic 
 Cubic 
 
0.6026 
0.6515 
0.9917 
1.0000 
 
0.5109 
0.4424 
0.9810 
1.0000 
 
0.3248 
-0.1395 
0.8671 
N/A 
 
5.59 
5.97 
1.10 
0.000 
 
- 
- 
Suggested 
- 
Response (Y2) 
 Linear 
 Second order 
 Quadratic 
 Cubic 
 
0.7987 
0.8008 
0.9926 
1.0000 
 
0.7522 
0.6812 
0.9832 
1.0000 
 
0.6563 
0.2993 
0.8823 
N/A 
 
6.92 
7.85 
1.80 
0.000 
 
- 
- 
Suggested 
- 
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Table: 11 Analysis of variance of calculated model 
Result of the ANOVA Drug Release 2 h (%)  Drug release 12h (%) 
 
Regression 
 
  Sum of squares 
  Degree of freedom (df) 
  Mean squares 
  F-value 
  P 
 
 
 
1014.56 
9 
112.73 
92.84 
<0.0001 
 
 
 
3070.19 
9 
341.13 
104.96 
<0.0001 
 
Residual 
 
  Sum of squares 
  Degree of freedom (df) 
  Mean squares 
 
 
 
8.50 
7 
1.21 
 
 
 
22.75 
7 
3.25 
 
Lack of Fit test 
 
  Sum of squares 
 Degree of freedom (df) 
  Mean squares 
  F-value 
  P 
  Correlation coefficient (R2) 
Correlation of variation (%CV) 
 
 
 
8.50 
3 
2.83 
- 
- 
0.9917 
14.19 
 
 
 
22.75 
3 
7.58 
- 
- 
0.9926 
2.50 
 
Optimization 1  
Drug release study was simulated in stomach pH and colon pH since the drug has an 
absorption window in colon. Minimum drug release was observed in formulation containing 
highest concentration of polymers (+1 level). The formulations containing similar amount of 
sodium alginate but with lower levels of tamarind gum showed higher drug release at acidic 
pH. Whereas, maximum drug release was observed in alkaline pH. Formulation containing 
sodium alginate and tamarind gum concentration at 0 and - 1 level, respectively, and tamarind 
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gum at + 1 level was found decreased drug release in acidic pH and prolonged the drug 
release upto 12 Hrs in alkaline pH. Similarly high amount of drug release was obtained in 
F11 containing -1 and 0 level of sodium alginate and tamarind gum concentration, and higher 
level of cross-linking agent. It could be inferred that both of the polymers were affecting drug 
release and were more or less compensating for each other as far as drug release was 
concerned. The regression analysis and ANOVA was represented in table 10 and 11. 
Table: 12 Experimental runs and observed values of responses for Box-Behnken design 
  INDEPENDENT 
VARIABLES 
DEPENDENT 
VARIABLES 
     ACTUAL PREDICTED 
RUNS BATCH A B C Y1 Y1 
1. F1 0 0 0 64.74 65.12 
2. F2 -1 1 0 65.01 64.76 
3. F3 1 -1 0 98.43 98.79 
4. F4 1 0 1 79.65 80.01 
5. F5 -1 0 1 51.24 50.63 
6. F6 1 1 0 97.82 98.26 
7. F7 0 1 -1 77.68 78.17 
8. F8 -1 0 -1 70.35 70.72 
9. F9 1 0 -1 94.87 95.38 
10. F10 -1 -1 0 65.25 64.71 
11. F11 0 1 1 61.04 61.59 
12. F12 0 -1 1 62.85 63.25 
13. F13 0 -1 -1 80.13 79.49 
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Figure No: 15 RSM of SA and TG on cumulative drug release at 12hrs at cross linking agent (10%) 
 
 
 
Figure No: 16 RSM of SA and Zinc sulphate on cumulative drug release at 12hrs at TG (4%) 
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Figure: 17 RSM of TG and Zinc sulphate on cumulative drug release at 12hrs at SA (6%) 
Optimization 2 
Drug release of chitosan succinate decorated alginate tamarind beads was carried out 
in acidic medium upto 2Hrs. Minimum drug release was observed in formulation  containing 
highest concentration of polymers (+1 level) and also cross linking agents ( 0 level). The 
results indicates that it can be observed that polymer crosslinking with glutraldehyde was 
successful, which led to uniform formation of beads. The mechanism of crosslinking of 
chitosan succinate with glutraldehyde is demonstrated that the free amino group of chitosan 
succinate is cross linked with aldehyde group of glutraldehyde to form schiff base (imine 
group).Whereas while increasing the concentration of glutraldehyde (+1 level) there is no 
much effect on control in drug release due to no free primary amino group present in chitosan 
backbone chain.  
The values of R- squared, Adj- squared, Pred R- squared, SD and % CV are shown in 
Table III along with the regression equation. Since the cubic model was aliased due to 
insufficient design points to estimate the coefficients, the quadratic model was chosen for its 
larger adjusted R- squared value. The ANOVA values for different responses are represented 
in Table IV, and all statistically significant (p < 0.05) coefficients are included in the 
equations. 
 
94 
As per the optimization design, a positive value shows favorable optimization, 
whereas a negative value shows an inverse relationship between the factor and the response. 
It is evident that all the three independent variables, namely the concentration of sodium 
alginate concentration (A), tamarind gum (B), zinc sulphate (C), have interactive effects on 
the estimated response, for example, drug release (Y1).  
Table: 13 Experimental runs and observed values of responses for Box-Behnken design  
  INDEPENDENT 
VARIABLES 
DEPENDENT VARIABLES 
     ACTUAL PREDICTED 
RUNS BATCH A B C Y1 Y1 
1. F14 0 0 0 2.36 2.17 
2. F15 -1 1 0 5.17 5.42 
3. F16 1 -1 0 9.31 9.73 
4. F17 1 0 1 2.63 2.37 
5. F18 -1 0 1 2.18 2.41 
6. F19 1 1 0 4.25 4.60 
7. F20 0 1 -1 15.43 15.92 
8. F21 -1 0 -1 18.82 18.59 
9. F22 1 0 -1 17.91 18.38 
10. F23 -1 -1 0 8.58 8.22 
11. F24 0 1 1 5.41 5.18 
12. F25 0 -1 1 6.23 6.53 
13. F26 0 -1 -1 31.09 30.44 
 
The model was significantly indicated by Model F-value of 7.89 (P = 0.0003). There 
is only 0.01% chance that this “Model F-Value” could occur due to noise. Model terms A, B, 
C, AC, BC and A 2 were significantly indicated by values of “ Prob> F ” <0.001. The amount 
of both polymer and cross-linking agent showed profound effect on in vitro drug release. The 
lack of fit was not significantly indicated by the “Lack of Fit F-value” of 0.26. There is a 
92.94% chance that a “Lack of Fit F-value” (quite high) could occur due to noise. The “ Pred 
R - squared ” of 0.9599 is in reasonable agreement with the “ Adj R - squared ” of 0.9083. “ 
Adeq Precision” at 13.522 indicates an adequate signal to use the model to navigate the 
design space. The regression analysis and ANOVA was represented in table 10 and 11. 
 
95 
 
Fig No: 18 Effect of SA - TG ratio and Chitosan succinate on drug release at 2hr from beads 
 
Fig No: 19 Effect of SA - TG ratio and Glutaraldehyde on drug release at 2hr from beads 
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Fig No: 20 RSM of Chitosan succinate and Glutaraldehyde on drug release at 2hr from beads 
 
CHARACTERIZATION OF CHITOSAN SUCCINATE DECORATED 
SODIUM ALGINATE TAMARIND GUM BEADS 
% Yield, DL and DEE  
For all the formulations the percentage yield, drug loading and drug entrapment 
efficiency were carried out for the optimized formulation the results are tabulated in the table 
No: 15. It is evident from the results use of chitosan succinate in chitosan succinate 
encrusted-alginate tamarind beads has already been recognized as stabilizing the “egg-box” 
structure and thereby reducing the problem of drug leaching during bead preparation. Thus, 
varying concentrations of chitosan succinate were added to the glutraldehyde solution in 
order to increase the entrapment efficiency. on increasing the chitosan succinate 
concentration, the drug loading and %EE increased significantly. This may be due to the fact 
that higher chitosan succinate concentration results in the formation of a denser matrix 
structure that probably decreases the loss of drug to the curing medium. In addition, 
electrostatic attraction between the negatively charged capecitabine and the positively 
charged chitosan succinate also becomes stronger, promoting the drug entrapment.[124] 
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Table No: 14% yield, DL and DEE for optimized formulation 
Formulation % yield DL DEE 
Optimized formulation 45.92 72.26 58.34 
 
MICROMERITIC PROPERTIES 
The results of the micromeritic studies are shown in table 15. The values of the 
different micromeritic parameters indicate the poor flow properties of pure drug while all the 
bead formulations showed acceptable flow properties and compression characteristics. The 
improved flow properties might be due to the spherical shape and smooth surface of the 
beads which show minimum resistance to flow. An increase in tamarind gum and chitosan 
succinate concentration led to an increase in particle size. This result is expected since 
capecitabine carried negative charge and electro statically interacted with tamarind gum and 
chitosan succinate, which would promote formation of beads through ionic cross-linking. 
Thus, as the tamarind gum and chitosan succinate concentration was increased; the particle 
size was also increased. The optimized batch had a mean size of around 1.017 mm. 
Table No: 15 Micrometric properties of pure drug and optimized formulation 
Batch 
 
Angle of 
repose (θ) 
Bulk 
density 
(gm/cm3) 
Tapped 
density 
(gm/cm3) 
Hausner‟s 
ratio 
Carr‟s 
index (%) 
Average 
particle 
size (mm) 
Pure drug 49.68 0.389 0.591 1.52 34.08 - 
Optimized 
formulation 
27.57 0.656 0.785 1.20 16.47 1.017 
 
SIZE, SHAPE AND SURFACE MORPHOLOGY  
In all formulations the alginate tamarind beads were more or less spherical in shape and the 
exterior surfaces were rough and covered with a network of small cracks and fissures, was 
shown in the figure 21-23.The drug was uniformly dispersed at the molecular level in the 
alginate beads. The spherical shape of the beads in wet state was usually lost after drying 
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especially for beads prepared with low concentration of SA and cross -linking agent. With the 
increase of SA concentration the shape of the beads retained considerably. It can be observed 
that polymer crosslinking with glutraldehyde was successful, which lead to uniform 
formation of spheres.[124] 
 
Fig No: 21 Scanning Electron Microscope (SEM) of the formulation (F8) Sodium alginate 
tamarind gum beads 
 
Fig No: 22 Scanning Electron Microscope image of the formulation (F27) shows spherical in 
shape and the exterior surfaces were rough and covered with a network of small cracks and 
fissures 
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Fig No: 23 The surface morphology of CS encrusted CP-loaded alginate-TG blend beads 
visualized by SEM. 
SWELLING INDEX  
Comparison of swelling behavior for alginate, Alginate and TG beads and CS 
encrusted beads was performed in two different pH (1.2and 7.4) simulating transition of 
beads in GIT. Swelling studies results shows the maximum swelling for all the batches of 
beads meant for simulated intestinal fluid (pH 7.4) as shown in Fig No. 24.  
The effect of pH on degree of swelling of beads is presented in Figure 8. The degree 
of swelling CS encrusted beads was found to be 100% and 0% soaked in 0.1N HCl (pH 1.2) 
and PBS (pH7.4) respectively. Whereas plain alginate beads was shown highest swelling, 
under acidic pH, which could probably due to formation of alginic acid regions through 
proton-zinc ion exchange and followed by solvent penetration into the gel-network.    
Alginate and tamarind gum blended beads, which is highly acid resistant is not 
sensitive to external acidic environment due to its higher viscosity, the polymer chains are 
bulkier, leading to less flexibility and hence more time for the polymer and solvent to 
interact. Although the swelling ability of  beads was found to be poorer in alkaline medium , 
the results reveals that zinc hydroxide was formed gradually as a result of the chelate 
complexing due to the disintegration of the alginate chains, which resulted in simultaneous 
increase in the degree of swelling. 
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The swelling of CS encrusted beads was completely controlled in acidic. This may be 
due to the fact that under acidic conditions, carboxylic groups present in the system exist in 
non-ionized form and are poorly hydrophilic, whereas in basic condition CS encrusted beads 
observed a maximum a degree of swelling rate (100%) due to the carboxylic groups exist in 
ionized form and are considerably hydrophilic. Thus, it may be concluded that CS encrusted 
beads, could be protected the drug from the harsh acidic environment of the stomach.  
 
    pH 1.2    pH7.4 
Figure: 24 Swelling Index of beads 
FTIR spectroscopy analyses 
FTIR spectroscopy is a useful tool in identification as well as purity of a compound. 
The principal absorption peaks of tamarind seed polysaccharide(fig 26) were found at 1034 
cm-1 (C-O-C, ether group absorbance), 1657 and 1742 cm-1 (C=O, aldehyde absorption), 
2924 cm-1 (C-H stretching), 3399cm-1 (primary OH) which indicate that isolated product was 
polysaccharide. 
FTIR spectrum of SA shows the characteristic peaks were appeared 1416 cm-1 and 
1616 cm−1, for symmetric and asymmetric –C=O stretching vibrations of -COO−anions, 
respectively. In addition, a wideband at 3441 cm−1was appeared due to the -OH stretching 
vibrations (Fig. 25). 
The FTIR spectra of prepared chitosan succinate (Fig. 28), showed amide carbonyl 
stretching in the range of 1640 – 1670 cm–1 and carboxylic carbonyl stretching in the range of 
1710 – 1720 cm–1. The selective acylation of the amino groups is probably due to their 
superior nucleophilic character compared to the surrounding hydroxyl groups. The new 
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absorption band at 1716 cm_1 was attributed to carbonyl group of ester group [C=O of O 
(COR)] and the peak at 1650.2cm_1 was assigned to the carbonyl group of acyl amino group. 
These result indicated that succinic group was introduced into the amino group and hydroxyl 
group. 
The Fig.27 shows the characteristics peaks of pure drug capecitabine at the wave 
number of 3520 cm-1 shows O-H stretching where the free hydroxyl group was present, the 
characteristic peak at 3215 cm-1 indicates the N-H stretching vibrations, at 2958cm-1 shows 
the C-H stretching, at wave number 2861 cm-1shows the presence of aldehyde group 
(CH=O), at 1716 and 1611 cm-1 indicates the presence of C=O carbonyl group of stretching 
vibrations, at 1502cm-1shows the N=O bending vibrations and further at 1245cm-1 shows the 
C-N bending vibrations. 
FT-IR spectrum of the CS encrusted beads was shown in Fig.29. The capecitabine 
characteristic peak was observed in the IR spectrum. The result reveals that there is no 
interaction between the drug and polymer. 
 
Fig No: 25 FT-IR Spectra of Sodium alginate 
 
Fig No: 26 FT-IR Spectra of isolated Tamarind gum  
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Fig No: 27 FT-IR Spectra of Pure drug Capecitabine 
 
 
Fig No: 28 FT-IR Spectra of synthesized Chitosan succinate 
 
 
Fig No: 29 FT-IR Spectra of the CS encrusted CP loaded alginate tamarind gum beads 
Thermal Analysis 
The thermo gram of capecitabine showed a sharp endothermic peak at 121.9°C, which 
nearly corresponded to the melting point of capecitabine (116–118°C). This peak was absent 
in the thermo grams of drug loaded beads formulation, confirming complete entrapment of 
the drug in polymer matrix.  
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Fig No: 30 DSC thermogram of Pure Drug 
 
 
Fig No: 31 DSC thermogram of Optimized formulation  
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IN VITRO DRUG RELEASE STUDY 
In-vitro drug release was carried out for the capecitabine loaded alginate tamarind 
gum beads in both acidic and alkaline pH. The result shows that drug release was observed in 
the acidic pH. With regard to alginate, in acidic medium, such as pH 1.0, as the chelate 
complexing of chains was destroyed as a result of the high concentration of H+, hydrogels 
swelled rapidly and even partially dissolved. But, as the pH varied from 3.0 to 7.0, the 
destruction due to H+ was not evident. With the continuous increase in the degree of 
alkalinity, zinc hydroxide was formed gradually as a result of the chelate complexing due to 
the disintegration of the alginate chains, which resulted in simultaneous increase in the drug 
release in acidic pH. Therefore to control the drug release in acidic beads the prepared CP 
loaded alginate tamarind gum beads were coated with chitosan succinate and cross-linked 
with glutraldehyde to provide the drug release in colon.  
The in vitro capecitabine release from ionotropically gelled CS encrusted beads 
showed prolonged release of drug over 12 h (Fig. 9). CP release from these CS encrusted 
beads in the acidic dissolution medium (0.1 N HCl; pH 1.2) was slow (less than 30.21% after 
2 h) and after that, faster CP release was observed in alkaline dissolution medium (phosphate 
buffer; pH7.4), comparatively. This may be due to the fact that these beads swelled quickly in 
alkaline dissolution medium than in acidic medium, and this led to comparative increased 
drug release in alkaline dissolution medium. In alkaline dissolution medium, probably a large 
swelling force was created by electrostatic repulsion between the ionized carboxylic acid 
groups of chitosan succinate-backbone. The cumulative drug release of CS encrusted CP 
loaded Tamarind- alginate blended beads after 10 h (R12h %) was within the range Fig of 
50.26 ± 1.47–98.37 ± 3.20. It was expected that in alkaline medium, the CS beads could swell 
upon liquid uptake during the initial period and a hydrated viscous layer around beads was 
formed. The drug subsequently diffuses through the hydrated viscous layer. It was observed 
from the dissolution profiles that the chitosan succinate beads showed an initial slower drug 
release and a subsequent faster drug release. The overall results suggest that the dried beads 
swell slightly in the stomach. When they are subsequently transferred to colon region, the 
bead s are begun to swell and they behave as matrices for sustained release of the drug. 
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Fig No: 32 Invitro drug release profile for Capecitabine loaded alginate/tamarind gum beads 
 
 
 
Fig No: 33Invitro drug release (2 HRS) for Chitosan succinate encrusted Capecitabine loaded 
alginate/tamarind gum beads 
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Fig No: 34 Invitro drug release for optimized formulation  
 
KINETIC EVALUATION OF IN VITRO RELEASE DATA 
Data obtained from in vitro release studies of optimized formulation was explored 
various kinetic models used are zero-order, first-order, and Higuchi equations. The data 
obtained from the in vitro release were fitted to various kinetic equations to determine the 
mechanism of drug release and release rate. As indicated by the higher correlation coefficient 
(r2 = 0.993), the drug release from CS beads followed the Higuchi model rather than the first-
order and zero order equations. These findings indicated that the drug release from the 
formulated CS beads was diffusion controlled. In sustained release formulations, diffusion, 
swelling and erosion are the three most important rate controlling mechanisms followed. The 
drug release from the polymeric system is mostly by diffusion and is best described by 
Fickian diffusion. But in case of formulations containing swelling polymers, other processes 
in addition to diffusion play an important role in exploring the drug release mechanisms.  
These processes include relaxation of polymer chains, imbibition of water causing 
polymers to swell and changing them from initial glassy to rubbery state. Due to swelling, 
considerable volume expansion take place leading to moving diffusion boundaries 
complicating the solution of Fick‟s second law of diffusion. So the release data were further 
treated by equation given by Ritger and Peppas or also called as the Power law . This 
equation is a generalization of the observation that superposes two apparently independent 
mechanism of drug transport, Fickian diffusion and a case-II transport describes drug release 
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from a swelling polymer. When n takes the value 0.5 it indicates diffusion-controlled drug 
release and for the value 1.0 indicates swelling-controlled drug release. Values of n between 
0.5 and 1.0 can be regarded as an indicator for the both phenomena (anomalous transport). 
These extreme values for the exponent n, 0.5 and 1.0, are only valid for slab geometry and for 
spheres and cylinders different values have been derived. For beads, a spherical geometry is 
considered and as per Ritger and Peppas n takes values in the range of 0.45–0.89 for 
anomalous transport. The value of n with regression coefficient for optimized formulation 
was found to be 0.9799 indicating the anomalous transport. The anomalous diffusion 
mechanism of drug release demonstrated both diffusion-controlled and swelling-controlled 
drug release from chitosan succinate beads containing Capecitabine. 
 
Table No: 16 Model fitting of in-vitro release studies 
Formulation 
code 
 
First order Zero order Higuchi Hixon-
Crowel 
Korsmeyer-
Peppas 
r2 n 
Optimized 
formulation  
 
0.8992 
 
0.9489 
 
0.993 
 
0.864 
 
0.9799 
 
 
Fig No: 35 Zero order kinetics of CS encrusted alginate tamarind gum beads 
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Fig No: 36 First order kinetics of CS encrusted alginate tamarind gum beads 
 
 
Fig No: 37 Higuchi order kinetics of CS encrusted alginate tamarind gum beads 
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Fig No: 38 Hixon- Crowel kinetics of CS encrusted alginate tamarind gum beads 
 
 
Fig No: 39 Korsmeyer-Peppas model of CS encrusted alginate tamarind gum beads 
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CONCLUSION 
The micro beads of capecitabine were formulated and optimized using Box – Behnken 
model. The quantitative responses of in vitro drug release for different combinations of 
independent variables, sodium alginate as release retarding polymer, Tamarind gum as acid 
resistant polymer and calcium chloride as cross-linking agent were obtained experimentally, 
and the results were found to fit the design model.  
The drug entrapment efficiency of the beads was increased while increasing 
concentration of tamarind gum. The quantitative effect of these factors at different levels on 
the responses could be predicted using polynomial equations, and high linearity was observed 
between predicted and actual values of response variables. The results of release studies 
indicate that chitosan succinate coated tamarind beads offer a high degree of protection from 
premature drug release in simulated upper GIT conditions.  
Chitosan Succinate coated tamarind beads deliver most of the drug load in the colon, 
an environment rich in bacterial enzymes that degrade the chitosan succinate and allow drug 
release to occur at the desired site. Thus, dual cross-linked CS decorated alg/tamarind beads 
may potential system for colon delivery of capecitabine for chemotherapy of cancer. 
 
 
 
 
. 
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